Curriculum Vitae for

Mark Brian Anderson, PhD, RAC 
.....................
Drugs ● Devices ● Biologics ● Combination Products ● Regulatory & Clinical Affairs ● Consultant ● Translational Medicine ● Business Development
I bring more than 18 years of experience in developing drugs, devices, biologics and combination products with experience in preclinical discovery, human clinical development and FDA regulatory affairs. Therapeutic area experience includes infectious disease, oncology, immunology, inflammatory diseases, cardiology, pulmonology, ENT, ophthalmology, dermatology and chronic non-healing wounds.

 
Business phone: +1-781-561-9005
Office: Norwell, MA

.....

Professional Experience

Markwebcopy.jpg

 

EXPERIENCE:
 

FDA Regulatory Affairs Contract Consultant,  

Fresenius Medical Care Waltham, Massachusetts, September 2014 – Present


  Fresenius Medical Care North America (FMC-NA) - Is the largest provider of renal care products and services in the nation, including state-of-the-art dialysis machines, dialyzers, medical devices, and pharmaceuticals.

 Services - Hemodialysis bloodlines, dialysis lines, hemodialysis components, Sorbent-based technologies, portable systems, dialyzers, software, 510(k), IDE, and FDA remediation.

     Deliverables – Review/Edit/Write regulatory documents; Claim substantiation review; FDA Additional Information (AI) responses; FDA pre-submission review (pre-Sub/pre-Q); device descriptions; materials of construction matrix; bill-of-materials (BOM); biocompatibility review and compliance for cytotoxicity ISO 10993-5, pyrogenicity ISO 10993-11, acute systemic toxicity ISO 10993-11, subchronic systemic toxicity ISO 10993-11, intracutaneous reactivity ISO 10993-10, sensitization ISO 10993-10, mutagenicity ISO 10993-3, genotoxicity ISO 10993-3, hemolysis direct/indirect ASTM F756-13, partial thromboplastin time ISO 10993-4, C3a complement activation ISO 10993-4, SC5b-9 complement activation ISO 10993-4, in-vitro thrombogenicity ASTM F1841-97; toxicological risk assessments (tolerable intakes, tolerable exposure, Margin of Safety); symbols and descriptions ISO 15223, EN 980; Labeling compliance per ANSI/AAMI/ISO 8638; Symbols compliance per ANSI/AAMI/ISO 15223-1 & -2; Sterilization an Shelf Life review per ANSI/AAMI/ISO11135-1, ANSI/AAMI/ISO11137-1, -2, & -3, ANSI/AAMI/ISO 11607-1, ANSI/AAMI/ST72, USP bacterial endotoxins, ANSI/AAMI/ISO 11737-1 & -2; ANSI/AAMI/ISO 17665-1 & -2, ANSI/AAMI/ISO 10993-7; Accelerated Aging compliance per ASTM F1980-07; instructions for use (IFU); Sterilization and Shelf Life; Software and cybersecurity ucm356190, AAMI/ANSI/IEC 62304:2006, and consensus standard compliance; Electromagnetic Compatibility; performance testing review e.g. stability and stress; Colorant/Pigment regulations and compliance; Colorant/Pigment MAF; materials science e.g. polymer ingredient review, slip agents, plasticizers, additives, annealing; Final finished device component specifications compliance to ISO 594-1 & -2; Quality Systems (21 CFR 820, 210, 211, ISO 13485, ISO 14971, NOM-241-SSA-1 MX); dialyzers BS EN ISO 8637 & 8638; Critical biocompatibility data evaluation; Substantial Equivalence (SE) tabulation matrix an substantiation; Extractable/Leachable compliance to ISO 10993-17 and USP standards (bench and clinical); Chemical Characterization of materials per ISO 10993-18; Human Factors ANSI/AAMI/ISO 622366 and IEC 60601; investigational device exemption (IDE) and 510(k) writing/editing, regulatory requirements documents, compliance wire, SOP compliance, Packaging compliance ISO/TS 16775; FDA recognized consensus standards/extent of recognition, regulatory requirements documentation (RRD), and relevant Guidance for Industry documents.

 

FDA Regulatory Affairs Contract Consultant,

ALKU Technologies, Andover, Massachusetts, September 2014 – Present

      FDA Regulatory Affairs consultant with ALKU. ALKU comprises: (1) ALKU Technologies specializing in Systems Applications & Products in Data Processing Services (SAP) & PeopleSoft Consultants; (2)      ALKU Quality – FDA Compliance and Quality Assurance Consulting Services; and (3) ALKU Government - Delivering solution-based Systems and Software Engineering, Cyber Security, Data and Military Intelligence Analytic Services for government customer and large systems integrator initiatives within the Intelligence Community, Department of Defense and Department of Energy space. 

 

Biotech Pharma Solutions;  March 2009 to Present

Contract Consultant, FDA/Global Regulatory Affairs & Business Development

 I bring more than 10 years of regulatory product experience in pharmaceuticals, medical devices, and biologics/biosimilars as a RAC certified professional. I work with many cross-functional teams to implement strategic regulatory strategies, data, and submission packages to US and international regulatory agencies. I bring an extensive background in regulatory affairs, business acumen, clinical pathology, chemistry/CMC, pharmacology, materials science, and microbiology towards the effective development of high quality compliant marketable products as a competitive advantage for my clients with strategic insight.

  Responsibilities include actively contributing to the development and implementation of strategies for specific projects including identifying and assessing regulatory risks, serving as the regulatory representative on project teams, FDA meetings, active involvement in the writing and review of regulatory submissions and interfacing with FDA and regulatory authorities, coordinating all aspects of regulatory submissions and proactively keeping updated on regulatory requirements in a fast-paced worldwide competitive marketplace.  Numerous successful submissions of INDs, NDA, BLA, 510(k)s, and PMAs for many companies.

 

      Published; US FDA Regulatory Affairs Handbook: From Principle to Practice; Bugs, Drugs & Attachments © 2013, 262 pages ISBN: 978-0-9898873-1-1.  See http://www.fdaregulatoryhandbook.com   
 
     Regulatory Affairs Filings; Work in contract research organizations on FDA Regulatory Affairs for drugs, medical devices, biologics and combination products. FDA regulatory pathways and compliance with IND, NDA [505(b)(1) or 505(b)(2)], BLA, Biosimilar, ANDA [505(j)], IDE, PMA, 510(k), IVD and HUD. Experience with CGMP 21 CFR 210, 211; GLP 21 CFR 58; QSR, ISO and ICH. Complete Filings, meetings and strategies with the FDA. Business development, partnering, licensing, development liaison with regulatory focus. Identify and meet with others working in areas of interest to consider future or current opportunities with KOLs. Attend investor conferences to learn of progress in products currently in development and corporate strategy to evolve with economic conditions. Participate in industry-wide conferences as invited; public speaking and board presentations. Study agent expertise in small molecules, proteins, biologics, microRNA, peptides, heterocyclic agents, monoclonal antibodies, complex molecules and innovative inorganic agents.  Consult on research of biofilm, drug resistance, bacteria, fungi and viruses.              Awards 

Anderson, M. 2011 Notable People in R&D - Article highlighting people recognized in the February issue of "R&D Directions" under Notable People in R&D Directions, page 16. . http://www.pharmalive.com/magazines/randd/

 

Contract Clients 

 

Contract Consultant, Regulatory Affairs, Clinical Affairs & Business Development

Nutrafortified - February 2012 to Present

Confidential consulting with CEOs, owners and growers to develop market plan for natural products,  regulatory affairs guidance – CFSAN (Center for Food Safety and Applied Nutrition), product prototyping, business planning and development.

Contract Consultant in Healthcare

MED360 / MNOW™ Experts - Boston & California Offices - February 2012 to Present

Contract Consult with financial institutions, life sciences foundations, and leading conference organizers. Confidential consulting through MNOW™ Experts “A Lead Physician Resource”. MED360 is built exclusively for decision makers as a tool to maximize their global healthcare knowledge to gain timely insights and ground-level analysis on issues affecting pharmaceutical, biotechnology, medical device, and healthcare service sub-sectors around the world in bringing products to market.

Contract Consultant: Chief Scientific Officer, Regulatory Affairs, Product Development

NovaBay Pharmaceuticals, Inc. Emeryville, CA – October 2009 to January 2012

NovaBay Pharmaceuticals is a clinical-stage startup company with a focus on infectious disease. Developed a robust pipeline of antimicrobial agents and new organic chloramines. Developed the final product line with NeutroPhase® for a cleared 510(k). Developed new use, formulations, clinical testing for a new medical device, ophthalmic solutions and gels, dermatological hydrogels, and urologic irrigation solutions as product lines. In developing the final product line responsible for regulatory compliance, phase 2 clinical trial support, work as team member with international affiliates on regional regulatory issues for IND, CTD, CGMP & CMC. Responsible for Clinical protocol and regulatory document review, Edit Pre-IND, clinical protocols, physician’s package insert, SOPs, and 510(k), submitted IND, WHO INN/USAN, FDA meetings, IND, and FDA EOP2a .

 

Business Development: International development included clinical research, animal models of disease and in vitro pharmacology with the University of Innsbruck, US development with Army CRADA with DOD. Wrote and funded tax grants: SBIR, Clinical development tax refund (funded). Worked closely with international affiliates concerning enabling research, clinical development, regulatory, compliance, regional regulatory issues, and business development. In/out-licensing presentations and negotiations

Scientific Leader on several programs: bacterial biofilm (published), resistance factors (published), virulence factors (published), onychomycosis (published), sinusitis (published), otitis media (submitted), and develop medical device opportunities (510(k) chronic non-healing wounds. Manage all aspects of the science and development of products and prototypes, pharmacology (DMPK, ADMET, PD), medicinal chemistry (SXR/SAR), pharmaceutical development, formulations, cell biology, analytical chemistry, and pathology. Scientific Advisory Board (SAB) management. CEO’s Executive Committee (EC) for corporate management, budgets, and interfacing with the Board of Directors (BOD). Manage key opinion leaders (KOLs). Manage patents, patent applications, outside council and execute publication strategy.

Product Development & Product Launch Team – 510(k) irrigation solution for infectious disease & chronic non healing wounds, ophthalmic solutions & ophthalmic hydrogels still in clinic, topical gel for infectious disease still in clinic, a topical solution for veterinary products as a gel and an ointment for infectious diseases. A combination product (drug plus device) for urinary catheter blockage and encrustation (UCBE), still in clinic. A drug device combination product (CAUTI), still in clinic.

 

Vice President of Research: Drug Discovery, Medicinal Chemistry and Program Development

Myriad Genetics & Myriad Pharmaceuticals– Salt Lake City, Utah – December 2003 to March 2009

     R&D Management: Drug discovery: best in class therapeutic candidates in the areas of cancer and infectious HIV, blood coagulation (hypercoagulopathy), blood brain barrier cancer treatments, Alzheimer’s disease, kinases and genetic associated diseases. Manage all aspects of small molecule drug discovery, analytical chemistry, hit-to-lead, review screening results, formulations, patent application writing and invention disclosures, lead  medicinal chemistry, manage candidate selection criteria, and candidate development for all drugs. Hands-on management of Pre-IND candidates, formulations, scale-up for INDs. Regulatory preparation to include,  Pre-IND writing/editing, IND submissions, Pre-FDA regulatory practice sessions, and Pre-IND Q&A. Managed internal teams and outsourced contractors to ensure compliance and adherence to guidelines. Science Formulations for end product to include, salt forms, solubility, polymorphs, formulations for intended use and route of administration, formulation patents, drying technologies, stability and bioavailability assessments. Scientific review leads of in-licensed materials in business development. WHO USAN/INN, in/out-licensing negotiations. Joint collaborative research committee with Abbott Labs; Chemical proteomics/biochemistry, translational medicine, and departmental management. Grants Funded: SBIR small molecule drug discovery  

Senior Director of Drug Discovery Chemistry R&D, Pharmacology and International Programs in Infectious Diseases

Elitra Pharmaceuticals, Inc. – San Diego, CA – June 2002 to November 2003

   Elitra identified more than 6,000 essential genes in eleven (11) bacterial and fungal infectious disease pathogens.
 
    Elitra became part of a 3-way merger called RS3 in which the IP was purchased by Trius, San Diego. Trius and Mycota (Elitra Canada) were acquired by Merck Pharmaceuticals. 
 
     Senior Director driving new screening technology to identify novel targets for known drugs and identify targets for new drugs (NCE). Working on gram-positive/negative infectious diseases including drug resistant diseases (e.g. MRSA). Identify targets for fungal infectious diseases (functional genomics on a genome-wide scale). Worked to validate antimicrobial agents against novel targets for Pre-IND R&D partnership opportunities. Work closely with internal teams and CROs for Pre-CMC development. Team lead with CROs on ongoing programs. 
 
      Senior Director driving leads to pre-IND candidates for all partnered programs. Work with the board of directors (BOD) in setting the corporate goals and objectives.  Manage R&D of all partnered programs. Liaison lead for international programs. Management of R&D screening results, lead selection, lead optimization, scale-up, microbiology, cell biology, and pharmacology (DMPK/ADMET).Grant writing against Yersinia pestis a Gram-negative rod-shaped bacterium belonging to the family Enterobacteriaceae (black plague). In-licensing negotiations and review of IND/NDA and product portfolios.  Management of medicinal chemistry, animal models of disease, patent invention disclosures, analytical chemistry, microbiology, cell-based assays, target validation, pharmacology (ADMET, PK PD), and external drug discovery chemistry teams. Grants: DOF Grant, Biodefense Biological Gram-negative rod-shaped bacterium and NIH, New Targets for Dangerous Pathogens.  

 

Associate Director of Medicinal Chemistry

Pfizer La Jolla (PGRD) – La Jolla, CA – October 1997 to June 2002

     Pfizer merger with Warner-Lambert (Agouron Pharmaceuticals).  Drug research & development included GnRH (neuroendocrine/cancer) program development candidate, Anticancer kinases, CHK-1 crystal structure/docking patent application , Antiviral therapeutics, Structure-based drug design (SBDD), Target library/combinatorial methodologies, IND candidate selection criteria. Management of > 35 PhD/MS chemists, students, and RAs Program management of > 30 PhD/MS pharmacologists, DMPK specialists, clinical development, internal CMC, biologists and development professionals, Merging and reorganization of departments. Part of the Pfizer oncology discovery advisory group (ODAG), Virology development group, Pfizer think-tank/incubator, strategic sourcing, Peptidomimetics, patent applications, manuscript writing, budgets, executive presentations, etc. 
 

             Awards

President's Award in drug discovery research; Pfizer/Agouron Phrmaceuticals (January 1999).

 

Senior Research Scientist and International Project Leader

Ligand Pharmaceuticals & Glycomed, Inc. – San Diego and Alameda CA – April 1992 to September 1997

      Ligand Pharmaceuticals merged with Glycomed, Inc. (Alameda, CA)  a company with multiple international collaborations and research in inflammatory diseases, cancer and biologics derived from an understanding of complex carbohydrates. My role included Phase 1 clinical development of GM-1998 a carbohydrate-based anti-cell adhesion agent. IND product advancement criteria for Sankyo Co. Ltd. and ARC (Canadian Alberta Research Council) for carbohydrate agents and small molecule therapeutic agents. Sankyo (Tokyo, Japan) collaboration therapeutic area program leader. ARC (Canada) Joint Collaborative Research Committee . Nonclinical (GMP) IND enabling animal models and CMC scale-up for GM-2296 & GM-2941. Alliance management: Johns Hopkins Asthma and Allergy Center, Baltimore, MD.; The University of Michigan Medical School Department of Pathology; The University of Michigan Medical School Department of Pharmacology; The MD Anderson Cancer Center in Houston Texas; and The University of Michigan at Kalamazoo.  
 
     Pre-IND R&D: GM1998, GM2941, GM2296, GM1292, GM3290, GM1658. Product development of small molecules, carbohydrates, hybrids (glycomimetics), and peptides. Therapeutic areas: Antitumor/anticancer, anti-inflammatory and antimicrobial carbohydrate-based therapeutics; asthma; cardiovascular disease (selectins, integrins, ABO antigen ((O, A, B, AB), Rhesus antigens  (+/- ve), including MNS, Kell and Lewis systems; cardiac ischemia-reperfusion injury; liver injury; pulmonary injury; Asthma; granulomatous vasculitis, eye disease and aberrant cell adhesion mediated disease. Inhibitors and modulators of E-, L-, and P-Selectins and integrins. 
 
 

Professional Presentations

2012 Presentations: R. Bryan Miller Symposium, March 15-16 at UC Davis. Invited speaker on “Hydrogel Drug Delivery for the Treatment of Impetigo”. 

2011 Presentations: NeutroPhase® Product Launch at the Symposium on Advanced Wound Care (SAWC), Las Vegas, NV; October 13 – 15, 2011.

Invited speaker at the Cambridge Healthtech Institute (CHI) Conference; San Diego, CA 2011.

Invited speaker at the 3rd Anti-Infectives Summit (IQPC/AIS); The Westin Philadelphia, PA; January 24 – 26, 2011.

Invited panel discussion on Corporate Collaborations & Partners at the 3rd Anti-Infectives Summit (IQPC/AIS); The Westin Philadelphia, PA; January 24 – 26, 2011.

Memberships: Regulatory Affairs Professionals Society (RAC); Association for Molecular Pathology (AMP); American Society for Investigative Pathology (ASIP); American Society of Microbiology (ASM); American Chemical Society (ACS).

Wound Care: Society for Advanced Wound Care (SAWC), Wound Healing Society (WHS).

Medical Devices: Multidisciplinary Alliance Against Device-Related Infections (MADRI), Pre-Filled Syringes (4th PFS London).

Ophthalmology: Association for Research in Vision and Ophthalmology (ARVO), American Academy of Ophthalmology (AAO).

Dermatology, Urology & Other: Interscience Conference on Antimicrobial Agents & Chemotherapy (ICAAC), and Infectious Diseases Society of America (IDSA)

 

 

 

 

Education Background

RAC Certification; US Regulatory Affairs Certification 2013

University of Massachusetts

2009 to 2010; Lowell, MA

Clinical Pathology Certification in the Clinical Laboratory and Nutritional Sciences Department

Clinical Pathology studies of the etiology, pathogenesis, morphologic features and clinical significance of disease, including the diagnosis, monitoring and prevention of disease. Clinical Pathology (graduate studies): Human anatomy, human physiology, genetics, immunology, microbiology, hematology, histocompatibility, cellular pathology, and clinical chemistry. Studies include diseases from a cellular and tissue perspective, autoimmune, cancer, immunology, cardiovascular, infectious diseases, pulmonary, urologic, dermal, ophthalmic, and more. Human Development and Pathophysiology: Dr. Alease Bruce; Advanced Pathophysiology: Dr. Kay Doyle, MT, ASCP; Health Data Analysis/Statistics: Dr. Beverly Volicer; and Infectious Diseases: Dr. Guixin He.

 

Harvard University

December 1989 to April 1992; Cambridge, MA

Harvard Officer & NSF Postdoctoral Research Fellow in the Department of Chemistry and Chemical Biology

Mentor: Professor Yoshito Kishi, Ph.D.

Palytoxin (PTX) is a complex marine natural product with 71 asymmetric centers isolated from soft coral and is considered to be one of the most toxic non-peptide substances known second to maitotoxin. Palytoxin targets the sodium-potassium pump protein via binding and "locking" it in a position allowing passive transport of both the sodium and potassium ions, thereby destroying the ion gradient that is essential for most cells. Toxicity symptoms are angina-like chest pains, tachycardia, unstable blood pressure, hemolysis, asthma-like breathing difficulties, and exaggerated T-wave in electrocardiograms, symptoms are rapid,  and death in minutes.

Palytoxin bioisosteres synthesis, incorporation and evaluation at the Harvard Medical School. Palytoxin carboxylic acid (PTC) derived from PTX and incorporate the new vinylogous urea mimic. Specially trained in the handling of PTX and PTC.  PTX intermediates and Palytoxin model systems. Methods included Kishi's Nickel‑Chromium coupling for the synthesis of the C‑1 to C‑16 and C‑1 to C‑25 Palytoxin model systems, worked on new synthetic building blocks, and carbon-glycosides. Testing of the novel palytoxin analogs were done at the Harvard University Medical School.

Purdue University

August 1984 to December 1989; West Lafayette, Indiana

Ph.D. NSF and NIH Graduate Research Associate in the Department of Chemistry

Mentor: Professor Phil. L. Fuchs, Ph.D.

Ph.D. Thesis: “New Methodologies Directed towards the Total Synthesis of Cytochalasins C & D.”

Background: The Cytochalasins can be used as “molecular tools” to better understand actin polymerization, cell motility, ruffling, cell division, contraction, cell stiffness, cytoskeletal movement and other biological processes. Constructed advanced intermediates and novel building blocks. Developed a unique Diels-Alder reaction, a novel intramolecular chiral acyl transfer strategy, expanded vinyl sulfone technologies, new cyclopentenylation methodology, anhydrous cerium (III) chloride methodologies, allylsilanes, beta-ethyl silyl thiol reagents (BEST), silicon and tin reagents, nucleophilic and electrophilic mercaptanylations and more.

Graduate Teaching Assistant , General Chemistry TA: Stoichiometry, prediction of reaction products, thermodynamics, nuclear chemistry, electrochemistry, chemical kinetics, gas laws, solubility, acid-base chemistry, etc., General Chemistry Laboratory TA: Applied laboratory techniques, Organic Chemistry TA for medical and healthcare fields, Organic Chemistry Laboratory TA for medical and healthcare fields: Applied laboratory techniques. Organic Chemistry for chemistry majors TA: Organic structures, properties, composition, reactions, synthesis, nomenclature, heterocyclic chemistry as well as phosphorus, silicon and sulfur.

University of Minnesota

August 1980 to June 1984; Minneapolis, MN

B.S. Chemistry, Undergraduate Research Thesis, with emphasis in Microbiology and Biochemistry

Mentors: Professor Edward Leete, Ph.D. (April 1928 - Feb 8, 1992) and Professor Marian Stankovich, Ph.D. (1948 - June 19, 2007)

Bachelor of Chemistry (B.S.) June 1984: Degree in chemistry with a emphasis in biochemistry and microbiology

Undergraduate research & thesis (CHM 3499) "Studies Directed Toward The Synthesis of 1,2,3,6‑Tetrahydronicotinic Acid and Retronecine for Their Use in Plant Biomimetic Syntheses" in the biogenesis of alkaloids (heterocyclic syntheses and plant chemical biology), and secondary plant metabolites with the late Professor Edward Leete. Niacin (vitamin B3 or nicotinic acid) prevents the deficiency disease pellagra. Tetrahydronicotinic acids are hypothetical plant intermediates of secondary plant metabolites and alkaloids.

Under graduate research on modified electrode surfaces with modified riboflavins examining the reduction potential of important enzymes with the late Professor M. T. Stankovich

Patents and Publications (a complete list is available upon request)

120+ patents and patent applications are available upon request

100+ Publications, invited presentations, and posters are available upon request

 

 

 

 

 

SELECTED CONTINUING EDUCATION COLLOQUIUMS

  • ARVO Clinical Trials Education Series: “Designing and Managing Clinical Trials in Eye Research.” May 1, 2010, 8:30 am – 5pm, Fort Lauderdale, FL. 
  • UCSD School of Medicine, Office of Continuing Medical Education ACS/UCSD Colloquium: “Angiogenesis Inhibitors in the Treatment of Solid Tumors”; Lee Rosen, M.D. January 22, 2001.
  • UCSD School of Medicine, Office of Continuing Medical Education ACS/UCSD Colloquium: “Nonmyeloablative Stem Cell Transplantation Using Low-dose Total Body Irradiation, Cyclosporine and MMF”; Peter McSweeney, M.D. February 26, 2001.
  • UCSD School of Medicine, Office of Continuing Medical Education ACS/UCSD Colloquium: “Current Therapeutic Opinions in the Management of B-Cell Malignancies”; Michael Keating, M.B., B.S. November 6, 2000.
  • UCSD School of Medicine, Office of Continuing Medical Education ACS/UCSD Colloquium: “New Endocrine Approaches for Breast Cancer: Prevention and Treatment”; C. Kent Osborne, M.D. October 23, 2000.
  • UCSD School of Medicine, Office of Continuing Medical Education ACS/UCSD Colloquium: “New Approaches to Therapy of Acute Myelogenous Leukemia”; Richard Stone, M.D. October 2, 2000.
  • UCSD School of Medicine, Office of Continuing Medical Education ACS/UCSD Colloquium: “Biology and Therapy of Advanced Prostate Oncology”; Christopher Logothetis, M.D. June 8, 1999.

 

CONFERENCES AND PROFESSIONAL MEMBERSHIP

  • 2012 Presentations: R. Bryan Miller Symposium, March 15-16 at UC Davis. Invited speaker on “Hydrogel Drug Delivery for the Treatment of Impetigo”.
  • 2011 Presentations: NeutroPhase® Product Launch at the Symposium on Advanced Wound Care (SAWC), Las Vegas, NV; October 13 – 15, 2011.
  • Invited speaker at the Cambridge Healthtech Institute (CHI) Conference; San Diego, CA 2011.
  • Invited speaker at the 3rd Anti-Infectives Summit (IQPC/AIS); The Westin Philadelphia, PA; January 24 – 26, 2011.
  • Invited panel discussion on Corporate Collaborations & Partners at the 3rd Anti-Infectives Summit (IQPC/AIS); The Westin Philadelphia, PA; January 24 – 26, 2011.
  • Memberships: Regulatory Affairs Professionals Society (RAC); Association for Molecular Pathology (AMP); American Society for Investigative Pathology (ASIP); American Society of Microbiology (ASM); American Chemical Society (ACS)
  • Wound Care: Society for Advanced Wound Care (SAWC), Wound Healing Society (WHS).
  • Medical Devices: Multidisciplinary Alliance Against Device-Related Infections (infectious disease)  (MADRI), Pre-Filled Syringes (4th PFS London).
  • Ophthalmology: Association for Research in Vision and Ophthalmology (ARVO), American Academy of Ophthalmology (AAO).
  • Dermatology, Urology & Other: Interscience Conference on Antimicrobial Agents & Chemotherapy (ICAAC), and Infectious Diseases Society of America (IDSA). 

 

 

OVERVIEW OF INTELLECTUAL PROPERTY

  • 100+ US & international issued and pending patent applications
  • 100+ Publications, invirted presentations and posters 

 

 .....

Markwebcopy.jpg

 

Biotech Pharma Solutions - Consulting Services

Drugs, Devices, Biologics, Combination Products, Business Development & Scientific Director
Orinda CA – March 2009 to September 2013
  • Idea to EOP2 POC
    • Agents & devices - drugs, devices, biologics and combination products
    • Business acumen – from Principle to Practice; the business of Science drives preclinical projects & ideas to IND, IDE or 510(k) submission(s) through successful work plans
    • Gap Analysis – critical review of project & program data, feasibility discussions and competitive landscaping
    • CRO – identify, build a work plan, monitor and review contracted services for scale up, CMC, formulations, containers & closures, 510(k) device prototypes, nonclinical pharmacology and clinical services
    • CMC - Scale up chemistry/processing and Pre-IND R&D of agents and formulations; Pre-IND R&D, candidate selection & progression criteria
    • GLP Nonclinical & Disease Models – in vitro & in vivo GLP pharmacology, safety, TOX, and relevant in vivo disease models
    • Pre-IND R&D – candidate advancement & selection criteria determination CMC
    • QSP - quantitative and systems pharmacology merges systems biology and pharmacology to advance the discovery, development and clinical use of therapeutic drugs
    • Regulatory - Pre-IND, IND, Phase 1 & 2, EOP2, FDA type A (e.g. SPA) & B (e.g. Pre-IND, EOP2, pre-Phase 3) meetings, IDE, 510(k), CGMP, GLP, QSR, eCTD and compliance
    • Intellectual property - medical & scientific writing, clinical summaries, invention brainstorming, patent writing/strategies (composition of matter, methods and utility), formulations, prototyping, presentations, and INN/USANC
    • Business Development – business development strategies, presentations, negotiations and in/out-licensing reviews
  • Clinical Development to Lifecycle Management
    • Strategic Planning – clinical trial design, FDA meetings, preapproval, approval and postapproval
    • FDA Meetings – FDA type A (e.g. SPA), B (e.g. Pre-IND, EOP2, Pre-Phase 3) and C meetings
    • Regulatory affairs – 21 CFR, ICH, FDA guidance documents and compliance assistance, eCTD, IND, NDA/BLA [505(b)(1), 505(b)(2)], IDE/PMA, 510(k) and ANDA [505(j)]
    • Clinical CRO – identify, build a work plan, monitor and review contracted services for scale up, CMC, formulations, containers & closures, 510(k) device prototypes, nonclinical pharmacology, disease models, safety, TOX, clinical services, guidance/review results from CRO, CGMP work, CMC, QSR, and manufacturing
    • Postapproval follow-up - SUPAC, QbD and PAS
    • Medical writing – clinical trial summaries, manuscripts and posters
    • Patent portfolio – coverage of API and/or drug product and RLD
  • Additional Topics and Disease Areas
    • Disease areas - oncology, infectious diseases, biofilm, drug resistance, immunology, cardiovascular, pulmonary, inflammatory diseases, aberrant cell adhesive diseases, biomarkers/surrogate markers, neurodegenerative, ENT, ophthalmology, dermatology, urology, and hospital treated wounds.
    • Agents - small molecules, large molecules, peptides, proteins, heterocyclic agents, monoclonal antibodies, medical devices (various), microRNA, complex oligosaccharides and inorganics
    • Devices – class I & II (e.g. irrigation solutions, patches, catheters, and implantable devices)
    • Consulting - clinical and preclinical R&D consulting subject to mutual agreement between the parties with pharmaceutical, biopharmaceutical, startups, nutraceutical, university and venture groups
    • Seminars/Lectures - infectious disease, biofilm, drug resistance, cancer, Alzheimer's disese, inflammatory disease, medicinal chemistry SXR, and the utilization of pharmacology data in drug design
  •  
    Selected Publication List
     
    NovaBay Pharmaceuticals, Inc. - Consultant                                                         
    Emeryville, CA – January 2012 to Current 
     
    Selected Publications
    • C. Eitzinger, S. Ehrlenbach, H. Lindner, L. Kremser, W. Gottardi, D. Debabov, M. Anderson, M. Nagl, D. Orth. N-chlorotaurine, a long-lived endogenous oxidant, inactivates Shiga toxin 2 of enterohemorrhagic  Escherichia coli. 2012 ICAAC, San Francisco, CA Poster F-2058.
    • Teuchner, B., Eitzinger, C., Lutz, M., Hager, T., Schmid, E., Bechrakis, N. E., Zuck, M., Jekle, A., Debabov, D., Anderson, M. and Nagl, M. (12Sept2012; online), N-chlorotaurine and its analogues N,N-dichloro-2,2-dimethyltaurine and N-monochloro-2,2-dimethyltaurine are safe and effective bactericidal agents in ex vivo corneal infection models. Acta Ophthalmologica. doi: 10.1111/j.1755-3768.2012.02501.x
    • Anderson, MB. Invited speaker at UC Davis 2012 R. Bryan Miller Symposium, March 15-16 at UC Davis Department of Chemistry, “Hydrogel Drug Delivery for the Treatment of Impetigo”.
    • Deepti Singhal, Andreas Jekle, Dmitri Debabov, Lu Wang, Bez Khosrovi, Mark Anderson,  Andrew Foreman, and Peter-John Wormald. Efficacy of NVC-422 against Staphylococcus aureus biofilms in a sheep biofilm model of sinusitis. International Forum of Allergy & Rhinology, 2012, 2, 309-315.
    • Louisa D’Lima, Lisa Friedman, Lu Wang, Ping Xu, Mark Anderson and Dmitri Debabov. No Decrease in Susceptibility to NVC-422 in Multiple Passage Studies against MRSA, S. aureus, P. aeruginosa and E. coli. Antimicrobial Agents and Chemotherapy 2012, 56, 2753–2755. First published February 2012, doi: 10.1128/​AAC.05985-11. 
    • US 2011/0190392 A1, Inventors: Azar Najafi, Bahram Memarzadeh, Sarah A. Ibrahim, Mark Brian Anderson. Polysaccharide Based Antimicrobial Formulations.  

    NovaBay Pharmaceuticals, Inc. - Chief Scientific Officer

    Emeryville, CA – October 2009 to January 2012

     
    Selected Publications
    • Anderson, MB. Invited speaker on Impetigo for the Cambridge Healthtech Institute (CHI) Conference; San Diego, CA 2011.
    • Anderson, MB Invited speaker on Impetigo at the 3rd Anti-Infectives Summit (IQPC/AIS); The Westin Philadelphia, PA; January 24 – 26, 2011.
    • Iovino, S.M., Krantz, K.D., Blanco, D.M., Fernández, J.A., Ocampo, N., Najafi, A., Memarzadeh, B., Celeri, C., Debabov, D., Khosrovi, B., and Anderson, M. International Journal of Clinical and Experimental Pathology. 2011; 4(6):587-595
    • 510(k) device in chronic non-healing wounds (submitted)
    • Darouiche, R., Najafi, R., Krantz, K., Debabov, D., Friedman, L., Khosrovi, B., Wang, L., Iovino, S., Anderson, M. Drugs of the Future 2011, 36(9): 651-656
    • Yoon J, Jekle A, Najafi R, Ruado F, Zuck M, Khosrovi B, Memarzadeh B, Debabov D, Wang L, Anderson M. Virucidal mechanism of action of NVC-422, a novel antimicrobial drug for the treatment of adenoviral conjunctivitis. Antiviral Res. 2011; 92: 470–478. PMID: 22024427.
    • NeutroPhase® Product Launch (vendor booth) and presentation assistance at the Symposium on Advanced Wound Care (SAWC), Las Vegas, NV; October 13 – 15, 2011.
    • Wound Healing Society (WHS)/ Symposium on Advanced Wound Care (SAWC) (poster GP-16), Dallas, TX
    Awards
    • 2011 Notable People in R&D - Article highlighting people recognized in the February issue of "R&D Directions" under Notable People in R&D Directions, page 16 2011
    Myriad Genetics & Myriad pharmaceuticals - Vice President
    Drug Discovery, Medicinal Chemistry & Early Clinical Development
    Salt Lake City, Utah – December 2003 to March 2009
     
    Selected Publications
    • 2012 – US 8258145. Method of treating brain cancer. Inventor: Sui Xiong Cai, Mark B Anderson, Adam Willardsen, Nilantha Sudath Sirisoma. Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs, and in particular to the use of these compounds in treating brain cancer.
    • David Gerrish, In Chul Kim, Dange V. Kumar, Harry Austin, Jennifer E. Garrus, Vijay Baichwal, Michael Saunders, Rena S. McKinnon, Mark B. Anderson, Robert Carlson, Esther Arranz-Plaza, Kraig M. Yager. Triterpene Based Compounds with Potent Anti-Maturation Activity Against HIV-1. Bioorganic & Medicinal Chemistry Letters 18 (2008) 6377-6380.
    • Full list of patents and publications available upon request
    Elitra Pharmaceuticals -  Senior Director of Drug Discovery Chemistry R&D, Pharmacology and International Programs in Infectious Diseases
    San Diego, CA – June 2002 to November 2003
     
    Selected Publications
    • Anderson, Mark B.; Roemer, Terry; Fabrey, Robyn. Progress in Antifungal Drug Discovery. Annual Reports in Medicinal Chemistry (2003), 38 163-172.
    Pfizer La Jolla (PGRD) - Associate Director of Medicinal Chemistry
    La Jolla, CA – October 1997 to June 2002
     
    Selected Publications
    • Anderes, Kenna L.; Luthin, David R.; Castillo, Rosemary; Kraynov, Eugenia A.; Castro, Mary; Nared-Hood, Karen; Gregory, Margaret L.; Pathak, Ved P.; Christie, Lance C.; Paderes, Genevieve; Vazir, Haresh; Ye, Qiang; Anderson, Mark B.; May, John M. Biological Characterization of A Novel, Orally Active Small Molecule Gonadotropin-Releasing Hormone (GNRH) Antagonist Using Castrated and Intact Rats. Journal of Pharmacology and Experimental Therapeutics (2003), 305(2), 688-695.
    • Full list of patents and publications available upon request
    Award
    • Agouron Pharmaceuticals President's Award in drug discovery research (January 1999).
    Ligand Pharmaceuticals & Glycomed, Inc. - Senior Research Scientist and International Project Leader
    San Diego and Alameda CA – April 1992 to September 1997
     
    Selected Publications
    • Kilgore, Kenneth S.; Powers, Karen L.; Imlay, Michelle M.; Malani, Anu; Allen, Douglas I.; Beyer, Jennifer T.; Anderson, Mark B.; Warren, Jeffrey S. The Carbohydrate Sialyl Lewisx (SLex) Sulfated Glycomimetic GM2941 Attenuates Glucan-Induced Pulmonary Granulomatous Vasculitis in the Rat. Journal of Pharmacology and Experimental Therapeutics (1998), 286(1), 439-446.
    • Kilgore, Kenneth S.; Tanhehco, Elaine J.; Park, James L.; Naylor, Keith B.; Anderson, Mark B.; Lucchesi, Benedict R. Reduction of Myocardial Infarct Size In vivo By Carbohydrate-Based Glycomimetics (GM1292, GM3290, GM1658). Journal of Pharmacology and Experimental Therapeutics (1998), 284(1), 427-435.
    • Kim, Mi-Kyeong; Brandley, Brian K.; Anderson, Mark B.; Bochner, Bruce S. Antagonism of Selectin-Dependent Adhesion of Human Eosinophils and Neutrophils By Glycomimetics and Oligosaccharide Compounds (SLex, GM1292, GM2296). American Journal of Respiratory Cell and Molecular Biology (1998), 19(5), 836-841.
    • F.J. Garcia-Criado, J.M. Palma-Vargas, J.J. Valdunciel-Garcia, A. Gomez-Alonso, O. Srivastava, A. Ezrin, M.B. Anderson, L.H. Toledo-Pereyra. Sulfo-Lewisx Diminishes Neutrophil Infiltration and Free Radicals with Minimal Effect on Serum Cytokines after Liver Ischemia and Reperfusion (GM-1998). J. Surgical Res. 1997, 70, 187-194
    • Full list of patents and publications available upon request

    .....

    Markwebcopy.jpg

    Education

    University of Massachusetts

    2009 to 2010 Lowell, MA
    Clinical Pathology Certification in the Clinical Laboratory and Nutritional Sciences Department
    • Advisor and Program Director/Professor and Chair: Dr. Eugene Rogers
    • Clinical Pathology studies of the etiology, pathogenesis, morphologic features and clinical significance of disease, including the diagnosis, monitoring and prevention of disease.
    • Clinical Pathology (graduate studies): Human anatomy, human physiology, genetics, immunology, microbiology, hematology, histocompatibility, cellular pathology, and clinical chemistry. Studies include diseases from a cellular and tissue perspective, autoimmune, cancer, immunology, cardiovascular, infectious diseases, pulmonary, urologic, dermal, ophthalmic, and more. Human Development and Pathophysiology: Dr. Alease Bruce; Advanced Pathophysiology: Dr. Kay Doyle, MT, ASCP; Health Data Analysis/Statistics: Dr. Beverly Volicer; and Infectious Diseases: Dr. Guixin He.
    Harvard University
    December 1989 to April 1992 Cambridge, MA
    Harvard Officer & NSF Postdoctoral Research Fellow in the Department of Chemistry and Chemical Biology
    • Mentor: Professor Yoshito Kishi, Ph.D.
    • Palytoxin (PTX) is a complex marine natural product with 71 asymmetric centers isolated from soft coral and is considered to be one of the most toxic non-peptide substances known second to maitotoxin. Palytoxin targets the sodium-potassium pump protein via binding and "locking" it in a position allowing passive transport of both the sodium and potassium ions, thereby destroying the ion gradient that is essential for most cells. Toxicity symptoms are angina-like chest pains, tachycardia, unstable blood pressure, hemolysis, asthma-like breathing difficulties, and exaggerated T-wave in electrocardiograms, symptoms are rapid,  and death in minutes.
    • Palytoxin bioisosteres synthesis, incorporation and evaluation at the Harvard Medical School. Palytoxin carboxylic acid (PTC) derived from PTX and incorporate the new vinylogous urea mimic. Specially trained in the handling of PTX and PTC.
    • PTX intermediates and Palytoxin model systems. Methods included Kishi's Nickel‑Chromium coupling for the synthesis of the C‑1 to C‑16 and C‑1 to C‑25 Palytoxin model systems, worked on new synthetic building blocks, and carbon-glycosides. Testing of the novel palytoxin analogs were done at the Harvard University Medical School.
    Purdue University
    August 1984 to December 1989 West Lafayette, Indiana
    Ph.D. NSF and NIH Graduate Research Associate in the Department of Chemistry
    • Mentor: Professor Phil. L. Fuchs, Ph.D.
    • Ph.D. Thesis: “New Methodologies Directed towards the Total Synthesis of Cytochalasins C & D.”
    • Background: The Cytochalasins can be used as “molecular tools” to better understand actin polymerization, cell motility, ruffling, cell division, contraction, cell stiffness, cytoskeletal movement and other biological processes.
    • Constructed advanced intermediates and novel building blocks. Developed a unique Diels-Alder reaction, a novel intramolecular chiral acyl transfer strategy, expanded vinyl sulfone technologies, new cyclopentenylation methodology, anhydrous cerium (III) chloride methodologies, allylsilanes, beta-ethyl silyl thiol reagents (BEST), silicon and tin reagents, nucleophilic and electrophilic mercaptanylations and more.
    Teaching Assistant
    • General Chemistry TA: Stoichiometry, prediction of reaction products, thermodynamics, nuclear chemistry, electrochemistry, chemical kinetics, gas laws, solubility, acid-base chemistry, etc.
    • General Chemistry Laboratory TA: Applied laboratory techniques
    • Organic Chemistry TA for medical and healthcare fields
    • Organic Chemistry Laboratory TA for medical and healthcare fields: Applied laboratory techniques
    • Organic Chemistry for chemistry majors TA: Organic structures, properties, composition, reactions, synthesis, nomenclature, heterocyclic chemistry as well as phosphorus, silicon and sulfur. The study and application of organic chemistry lie on a continuum, but individuals with interests in these areas tend to have one thing in common; they seek to understand how chemical structure correlates with biological activity (chemical biology).
    Selected Publications
    • Full list of patents and publications available upon request
    University of Minnesota
    August 1980 to June 1984 Minneapolis, MN
    B.S. Chemistry, Undergraduate Research Thesis, with emphasis in Microbiology and Biochemistry
    • Mentors: Professor Edward Leete, Ph.D. (April 1928 - Feb 8, 1992) and Professor Marian Stankovich, Ph.D. (1948 - June 19, 2007)
    • Bachelor of Chemistry (B.S.) June 1984: Degree in chemistry with a emphasis in biochemistry and microbiology
    • Undergraduate research & thesis (CHM 3499) "Studies Directed Toward The Synthesis of 1,2,3,6‑Tetrahydronicotinic Acid and Retronecine for Their Use in Plant Biomimetic Syntheses" in the biogenesis of alkaloids (heterocyclic syntheses and plant chemical biology), and secondary plant metabolites with the late Professor Edward Leete. Niacin (vitamin B3 or nicotinic acid) prevents the deficiency disease pellagra. Tetrahydronicotinic acids are hypothetical plant intermediates of secondary plant metabolites and alkaloids.
    • Under graduate research on modified electrode surfaces with modified riboflavins examining the reduction potential of important enzymes with the late Professor M. T. Stankovich
    • Chemistry Fraternity: AXΣ (Alpha Chi Sigma)
    • Biology, cell biology and plant taxonomy from Lakewood Community College/Century College Jan 1979/May 1980

    References

    Upon request only

    LinkedIn: http://www.linkedin.com/in/markbanderson; Cyber Recommendations 

    Awards

    • 2011 Notable People in R&D - Article of one of nine people recognized in the February issue of "R&D Directions" under Notable People in R&D Directions, page 16 2011. http://www.pharmalive.com/magazines/randd/
    • 2009 Cambridge Who’s Who
    • 2003 Strathmore's Who's Who - in Leadership and Achievement
    • 2003 United Who's Who - of Executives and Professionals
    • 1999 President’s Award - Agouron Pharmaceuticals "President's Award in Drug Discovery, January 1999

    ..................

    Presentations & Publications

    Infectious Disease & Medical Devices

    • Several manuscripts accepted and in preparation
    • Teuchner, B., Eitzinger, C., Lutz, M., Hager, T., Schmid, E., Bechrakis, N. E., Zuck, M., Jekle, A., Debabov, D., Anderson, M. and Nagl, M. (12Sept2012; online), N-chlorotaurine and its analogues N,N-dichloro-2,2-dimethyltaurine and N-monochloro-2,2-dimethyltaurine are safe and effective bactericidal agents in ex vivo corneal infection models. Acta Ophthalmologica. doi: 10.1111/j.1755-3768.2012.02501.x
    • Deepti Singhal, Andreas Jekle, Dmitri Debabov, Lu Wang, Bez Khosrovi, Mark Anderson,  Andrew Foreman, and Peter-John Wormald. Efficacy of NVC-422 against Staphylococcus aureus biofilms in a sheep biofilm model of sinusitis. International Forum of Allergy & Rhinology, 2012, 2, 309-315.
    • Louisa D’Lima, Lisa Friedman, Lu Wang, Ping Xu, Mark Anderson and Dmitri Debabov. No Decrease in Susceptibility to NVC-422 in Multiple Passage Studies against MRSA, S. aureus, P. aeruginosa and E. coli. Antimicrobial Agents and Chemotherapy 2012, 56, 2753–2755. First published February 2012, doi: 10.1128/​AAC.05985-11.  
    • Martini, A. Hammerer-Lercher, M. Zuck, A. Jekle, D. Debabov, M. Anderson, M. Nagl. Antimicrobial and Anticoagulant Activity of N-chlorotaurine (NCT) N,N-dichloro-2,2-dimethyltaurine (NVC-422) and N-monochloro-2,2-dimethyltaurine (NVC-612) in Human Blood. Antimicrobial Agents and Chemotherapy 2012, 56(4):1979-1984. [Epub ahead of print], PMID: 22252818.
    • M.A. Ghannoum, L. Long, A.J. Cirino, A.R. Miller, R. Najafi, L. Wang, K. Sharma, M. Anderson, and B. Memarzadeh. Efficacy of NVC-422 in the treatment of dermatophytosis caused by Trichophyton mentagrophytes using a Guinea Pig Model. International Journal of Dermatology. In press 2012.
    • Rabih Darouiche, Ramin (Ron) Najafi, Kenneth Krantz, Dmitri Debabov, Lisa Friedman, Behzad Khosrovi, Lu Wang, Susan Iovino, Mark Anderson. NVC-422. Drugs of the Future 2011, 36(9): 651-656.
    • Susan M. Iovino, Kenneth D. Krantz, Daisy M. Blanco, Josefina A. Fernández, Naomi Ocampo, Azar Najafi, Bahram Memarzadeh, Chris Celeri, Dmitri Debabov, Behzad Khosrovi, and Mark Anderson. NVC-422 Topical Gel for the Treatment of Impetigo. International Journal of Clinical and Experimental Pathology. 2011; 4(6):587-595.
    • Yoon J, Jekle A, Najafi R, Ruado F, Zuck M, Khosrovi B, Memarzadeh B, Debabov D, Wang L, Anderson M. [Epub ahead of print; Oct 15] Virucidal mechanism of action of NVC-422, a novel antimicrobial drug for the treatment of adenoviral conjunctivitis. Yoon J, Jekle A, Najafi R, Ruado F, Zuck M, Khosrovi B, Memarzadeh B, Debabov D, Wang L, Anderson M. Antiviral Res. 2011; 92: 470–478. PMID: 22024427.
    • D. Debabov, C. Celeri, L. Friedman, R. Najafi, and M. Anderson. NVC-422 is Effective against Gram-positive and Gram-negative Pathogens including MDR Strains. Antimicrobial Agents and Chemotherapy. In Press 2012.
    • D. Debabov, C. Celeri, Lu Wang, Ping Xu, L. Friedman, D. Sahm, R. Najafi, and M. Anderson. In vitro Activity of NVC-422, a Unique, Broad Spectrum Antimicrobial Compound, against Key Gram-positive and Gram-negative Bacterial Pathogens. Accepted.
    • Andreas Jekle, Chris Celeri, Meghan Zuck, Ping Xu, Lu Wang, Mark Anderson and Dmitri Debabov. Activity of NVC-422 against Viral Ocular Pathogens. Investigative Ophthalmology & Visual Science (ARVO Journal). In Press 2012.
    • Timothy P. Shiau, Eric D. Turtle, Charles Francavilla, Nichole J. Alvarez, Meghan Zuck, Lisa Friedman, Donogh J. R. O’Mahony, Eddy Low, Mark B. Anderson, Ramin (Ron) Najafi, Rakesh K. Jain Novel 3-chlorooxazolidin-2-ones as antimicrobial agents. Bioorganic & Medicinal Chemistry Letters 2011; (21) 3025-3028.
    • Eddy Low, Bum Kim, Charles Francavilla, Timothy P. Shiau, Eric D. Turtle, Donogh J. R. O’Mahony,Nichole Alvarez, Ashley Houchin, Ping Xu, Meghan Zuck, Chris Celeri, Mark B. Anderson, Ramin (Ron) Najafi, Rakesh K. Jain. Structure stability/activity relationships of sulfone stabilized N,N-dichloroamines . Bioorganic & Medicinal Chemistry Letters 2011; (21) 3682-3685.
    • Charles Francavilla, Eric D. Turtle, Bum Kim, Donogh J. R. O’Mahony, Timothy P. Shiau, Eddy Low, Nichole J. Alvarez, Chris E. Celeri, Louisa D’Lima, Lisa C. Friedman, Francis S. Ruado, Ping Xu, Meghan E. Zuck, Mark B. Anderson, Ramin (Ron) Najafi, Rakesh K. Jain, Novel N-chloroheterocyclic antimicrobials. Bioorganic & Medicinal Chemistry Letters 2011; (21) 3029-3033.
    • David Gerrish, In Chul Kim, Dange V. Kumar, Harry Austin, Jennifer E. Garrus, Vijay Baichwal, Michael Saunders, Rena S. McKinnon, Mark B. Anderson, Robert Carlson, Esther Arranz-Plaza, Kraig M. Yager. Triterpene Based Compounds with Potent Anti-Maturation Activity Against HIV-1. Bioorganic & Medicinal Chemistry Letters 18 (2008) 6377-6380.
    • Anderson, Mark B.; Roemer, Terry; Fabrey, Robyn. Progress in Antifungal Drug Discovery. Annual Reports in Medicinal Chemistry (2003), 38 163-172.

    Neuroendocrine & Oncology

    • Jeffrey W. Lockman, Yevgeniya Klimova, Mark B. Anderson & J. Adam Willardsen. Synthesis of Substituted Quinazolines: Application to the Synthesis of Verubulin.  Synthetic Communications, 2012, 42, 1715-1723.
    • Nilantha Sirisoma, Azra Pervin, Hong Zhang, Songchun Jiang, J. Adam Willardsen, Mark B. Anderson, Gary Mather, Christopher M. Pleiman, Shailaja Kasibhatla, Ben Tseng, John Drewe, Sui Xiong Cai. Discovery of N-methyl-4-(4-methoxyanilino)quinazolines as potent apoptosis inducers. Structure–activity relationship of the quinazoline ring (EP128495, MPC-6827, Azixa®).  Bioorganic & Medicinal Chemistry Letters, 2010, 20, 2330-2334. 
    • Paul R. Sebahar, J. Adam Willardsen and Mark B. Anderson. Anticancer Agents: VTA or VDA. Current Bioactive Compounds, 2009, 5(1), 79-97.
    • Nilantha Sirisoma, Azra Pervin, Hong Zhang, Songchun Jiang, J. Adam Willardsen, Mark B. Anderson, Gary Mather, Christopher M. Pleiman, Shailaja Kasibhatla, Ben Tseng, John Drewe, Sui Xiong Cai. Discovery of N-(4-Methoxyphenyl)-N,2-Dimethylquinazolin-4-Amine, A Potent Apoptosis Inducer and Efficacious Anticancer Agent with High Blood Brain Barrier Penetration. J. Med. Chem., 2009, 52 (8), 2341-2351.
    • Nilantha Sirisoma, Shailaja Kasibhatla, Azra Pervin, Hong Zhang, Songchun Jiang, J. Adam Willardsen, Mark Anderson, Christopher M. Pleiman, Ben Tseng, John Drewe, Sui Xiong Cai. Discovery of 2-Chloro-N-(4-Methoxyphenyl)-N-Methylquinazolin-4-Amine (EP128265, MPI-0441138) As An Inducer of Apoptosis with In Vivo Activity. J. Med. Chem. 2008, 51, 4771-4779.
    • Li, Haitao; Anderes, Kenna L.; Kraynov, Eugenia A.; Luthin, David R.; Do, Quyen-Quyen; Hong, Yufeng; Tompkins, Eileen; Sun, Eric T.; Rajapakse, Ranjan; Pathak, Ved P.; Christie, Lance C.; Vazir, Haresh; Castillo, Rosemary; Gregory, Margaret L.; Castro, Mary; Nared-Hood, Karen; Paderes, Genevieve; Anderson, Mark B. Discovery of A Novel, Orally Active, Small Molecule Gonadotropin-Releasing Hormone (GNRH) Receptor Antagonist. [ERRATUM TO DOCUMENT CITED IN CA145:020415]. Journal of Medicinal Chemistry (2006), 49(19), 5849.
    • Li, Haitao; Anderes, Kenna L.; Kraynov, Eugenia A.; Luthin, David R.; Do, Quyen-Quyen; Hong, Yufeng; Tompkins, Eileen; Sun, Eric T.; Rajapakse, Ranjan; Pathak, Ved P.; Christie, Lance C.; Vazir, Haresh; Castillo, Rosemary; Gregory, Margaret L.; Castro, Mary; Nared-Hood, Karen; Paderes, Genevieve; Anderson, Mark B. Discovery of A Novel, Orally Active, Small Molecule Gonadotropin-Releasing Hormone (GNRH) Receptor Antagonist. Journal of Medicinal Chemistry (2006), 49(11), 3362-3367.
    • Anderes, Kenna L.; Luthin, David R.; Castillo, Rosemary; Kraynov, Eugenia A.; Castro, Mary; Nared-Hood, Karen; Gregory, Margaret L.; Pathak, Ved P.; Christie, Lance C.; Paderes, Genevieve; Vazir, Haresh; Ye, Qiang; Anderson, Mark B.; May, John M. Biological Characterization of A Novel, Orally Active Small Molecule Gonadotropin-Releasing Hormone (GNRH) Antagonist Using Castrated and Intact Rats. Journal of Pharmacology and Experimental Therapeutics (2003), 305(2), 688-695.
    • Shackelford, Scott A.; Anderson, Mark B.; Christie, Lance C.; Goetzen, Thomas; Guzman, Mark C.; Hananel, Martha A.; Kornreich, Wayne D.; Li, Haitao; Pathak, Ved P.; Rabinovich, Alex K.; Rajapakse, Ranjan J.; Truesdale, Larry K.; Tsank, Stella M.; Vazir, Haresh N. Electrophilic Tetraalkylammonium Nitrate Nitration. II. Improved Anhydrous Aromatic and Heteroaromatic Mononitration with Tetramethylammonium Nitrate and Triflic Anhydride, Including Selected Microwave Examples. Journal of Organic Chemistry (2003), 68(2), 267-275. Erratum to CA138:169603 Journal of Organic Chemistry (2003), 68(7), 2986.
    • Iatsimirskaia, Eugenia A.; Gregory, Margaret L.; Anderes, Kenna L.; Castillo, Rosemary; Milgram, K. Eric; Luthin, David R.; Pathak, Ved P.; Christie, Lance C.; Vazir, Haresh; Anderson, Mark B.; May, John M. Effect of Testosterone Suppression On The Pharmacokinetics of A Potent GnRH Receptor Antagonist. Pharmaceutical Research (2002), 19(2), 202-208.
    • Luthin, David R.; Hong, Yufeng; Tompkins, Eileen; Anderes, Kenna L.; Paderes, Genevieve; Kraynov, Eugenia A.; Castro, Mary A.; Nared-Hood, Karen D.; Castillo, Rosemary; Gregory, Margaret; Vazir, Haresh; May, John M.; Anderson, Mark B. Characterization of Mono- and Diaminopyrimidine Derivatives as Novel, Nonpeptide Gonadotropin Releasing Hormone (GnRH) Receptor Antagonists. Bioorganic & Medicinal Chemistry Letters (2002), 12(24), 3635-3639.
    • Luthin, David R.; Hong, Yufeng; Pathak, Ved P.; Paderes, Genevieve; Nared-Hood, Karen D.; Castro, Mary A.; Vazir, Haresh; Li, Haitao; Tompkins, Eileen; Christie, Lance; May, John M.; Anderson, Mark B. The Discovery of Novel Small Molecule Non-Peptide Gonadotropin Releasing Hormone (GnRH) Receptor Antagonists. Bioorganic & Medicinal Chemistry Letters (2002), 12(23), 3467-3470.

    Pulmonary, Cardiovascular & Asthma

    • Kilgore, Kenneth S.; Powers, Karen L.; Imlay, Michelle M.; Malani, Anu; Allen, Douglas I.; Beyer, Jennifer T.; Anderson, Mark B.; Warren, Jeffrey S. The Carbohydrate Sialyl Lewisx (SLex) Sulfated Glycomimetic GM2941 Attenuates Glucan-Induced Pulmonary Granulomatous Vasculitis in the Rat. Journal of Pharmacology and Experimental Therapeutics (1998), 286(1), 439-446.
    • Kilgore, Kenneth S.; Tanhehco, Elaine J.; Park, James L.; Naylor, Keith B.; Anderson, Mark B.; Lucchesi, Benedict R. Reduction of Myocardial Infarct Size In vivo By Carbohydrate-Based Glycomimetics (GM1292, GM3290, GM1658). Journal of Pharmacology and Experimental Therapeutics (1998), 284(1), 427-435.
    • Kim, Mi-Kyeong; Brandley, Brian K.; Anderson, Mark B.; Bochner, Bruce S. Antagonism of Selectin-Dependent Adhesion of Human Eosinophils and Neutrophils By Glycomimetics and Oligosaccharide Compounds (SLex, GM1292, GM2296). American Journal of Respiratory Cell and Molecular Biology (1998), 19(5), 836-841.
    • Anderson, M.B., Kilgore, K.S., et al. Additional Novel Glycomimetics That Attenuated Glucan-Induced Pulmonary Granulomatous Vasculitis in the Rat. Unpublished.
    • Garcia-Criado, F. J.; Palma-Vargas, J. M.; Valdunciel-Garcia, J. J.; Gomez-Alonso, A.; Srivastava, O.; Ezrin, A.; Anderson, M. B.; Toledo-Pereyra, L. H. Sulfo-Lewisx Diminishes Neutrophil Infiltration and Free Radicals with Minimal Effect On Serum Cytokines After Liver Ischemia and Reperfusion (GM1998). Journal of Surgical Research (1997), 70(2), 187-194.
    • Musser, John H.; Anderson, Mark B.; Fugedi, Peter. Glycomimetics: An Approach To Discovering Leads For Novel Therapeutics. Pharmaceutical News (1996), 3(5), 11-17.
    • Musser, John H.; Fugedi, Peter; Anderson, Mark Brian; Rao, Narasinga; Peto, Csaba; Tyrrell, Dave; Holme, Kevin; Tressler, Rob. Carbohydrates as A Source of Molecular Diversity For Drug Discovery. Drug News & Perspectives (1996), 9(3), 133-141.
    • M. K. Kim, B. K. Brandley, M. B. Anderson and B. S. Bochner. Antagonism of Human Neutrophil (Neu) and Eosinophil (EOS) Adhesion By Glycomimetics and Oligosaccharide Compounds. The American Academy of Allergy and Immunology, abstract in J. Allergy Clin Immunol., 1995, 95:220.
    • Musser, John H.; Anderson, Mark B.; Levy, Daniel E. Glycomimetics as Selectin Inhibitors. Current Pharmaceutical Design (1995), 1(2), 221-32.
    • Rao, B. N. Narasinga; Anderson, Mark B.; Musser, John H.; Gilbert, James H.; Schaefer, Mary E.; Foxall, Carrol; Brandley, Brian K. Sialyl Lewisx Mimics Derived From A Pharmacophore Search Are Selectin Inhibitors with Anti-Inflammatory Activity. Journal of Biological Chemistry (1994), 269(31), 19663-6.
    • John H. Musser, Péter Fügedi and Mark Brian Anderson. Chapter Twenty‑Two: Carbohydrate Based Therapeutics. Burger's Medicinal Chemistry, Chapter 22, Fifth Edition 1994, pages 901‑947.

    Natural Products

    • Anderson, M. B.; Lamothe, M.; Fuchs, P. L. Synthesis Via Vinyl Sulfones. 41. Cytochalasin, Natural Product Support Studies. 16. Intramolecular Acylation of An Alpha- Sulfonyl Anion Generated Via Halogen-Metal Exchange of An Alpha- Halosulfone Bearing An Unsymmetrical Anhydride. Tetrahedron Letters (1991), 32(35), 4457-60.
    • Lamothe, M.; Anderson, M. B.; Fuchs, P. L. Synthesis Via Vinyl Sulfones. 40. Cytochalasin, Natural Product Support Studies. 15. Scope and Limitations in The Use of Alpha-Silyl and Alpha-Stannyl Sulfones as Latent Alpha-Sulfonyl Anions. Synthetic Communications (1991), 21(15-16), 1675-93.
    • Wood, K. V.; Rothwell, A. P.; Anderson, M. B.; Fuchs, P. L. The Intramolecular Migration of A Trimethylsilyl Group Located Alpha To A Sulfone in Substituted Cyclohexyl Systems. Rapid Communications in Mass Spectrometry (1990), 4(1), 1-4.
    • Wood, K. V.; Rothwell, A. P.; Anderson, M. B.; Lamothe, M.; Fuchs, P. L. Mass Spectra of Substituted O-Trimethylsilylphenyl Sulfones. Organic Mass Spectrometry (1990), 25(8), 423-5.
    • Anderson, M. B.; Fuchs, P. L. Synthesis Via Vinyl Sulfones. 37. Cytochalasin, Natural Product Support Studies. 11. Alpha-Silyl Sulfones as Latent Alpha-Sulfonyl Anions. Fluoride-Promoted Intramolecular 1,2-Additions To Aldehydes as The Basis of A New Cyclopentenylation Strategy. Journal of Organic Chemistry (1990), 55(1), 337-42.
    • Anderson, Mark Brian. New Methodologies Directed Towards The Total Synthesis of Cytochalasin, Natural Product C and D. (1989), 498 pp. CAN 114:101467 AN 1991:101467.
    • Wood, Karl V.; Rothwell, Arlene P.; Anderson, Mark B.; Fuchs, P. L. Evidence For Competitive Intramolecular Trimethylsilyl Rearrangement To Oxygen and Sulfur in Beta-Trimethylsilylethylthiol Esters. Rapid Communications in Mass Spectrometry (1988), 2(2), 38-40.
    • Anderson, M. B.; Ranasinghe, M. G.; Palmer, J. T.; Fuchs, P. L. CYTOCHALASIN, NATURAL PRODUCT SUPPORT STUDIES. 10. Nucleophilic and Electrophilic Mercaptanylations Via 2-(Trimethylsilyl)Ethanethiol-Derived Reagents. Journal of Organic Chemistry (1988), 53(13), 3125-7.
    • Anderson, M. B.; Fuchs, P. L. Cytochalasin, Natural Product Support Studies. Part 9. An Efficient Method For Conversion of Carboxylic Acid Derivatives To Allylsilanes. Synthetic Communications (1987), 17(6), 621-35.
    Posters

    Infectious Disease & Medical Devices

    • 2012 ICAAC (F-2058) – C. Eitzinger, S. Ehrlenbach, H. Lindner, L. Kremser, W. Gottardi, D. Debabov, M. Anderson, M. Nagl, D. Orth. N-chlorotaurine, a long-lived endogenous oxidant, inactivates Shiga toxin 2 of enterohemorrhagic  Escherichia coli. 2012 ICAAC, San Francisco, CA Poster F-2058.
    • 2012 SAWC – J.R. Crew, R. Varilla, T.A. Rocas, D. Debabov, S. Rani, L. Wang, R. Najafi, and M.B. Anderson. Conquering Chronic Non-Healing Wounds with Pure Hypochlorous Acid. Symposium on Advanced Wound Care, Atlanta GA, April 2012.
    • 2011 ICAAC (E-135) - L. D’Lima, L. Friedman, P. Xu, L. Wang, M. Anderson, D. Debabov, NVC-422 Does not Generate Resistance in MRSA, Staphylococcus aureus, Pseudomonas aeruginosa and Escherichia coli after Multiple Serial Passages at Sub-Inhibitory Concentrations. Interscience Conference on Antimicrobial Agents & Chemotherapy Medical Conference Poster E-135. Chicago, Il; September 17-20, 2011.
    • 2011 ICAAC (E-133) - C. Eitzinger, B. Teuchner, M. Lutz, T. Hager, E. Schmid, M. Zuck, A. Jekle, D. Debabov, N. E. Bechrakis, M. Anderson and M. Nagl. N,N-dichloro-2,2-dimethyltaurine, N-monochloro- 2,2-dimethyltaurine, and N-chlorotaurine are Safe and Effective Bactericidal Agents in Corneal Models Division of Hygiene and Medical Microbiology; Department of Ophthalmology; Department of Pathology, Innsbruck Medical University, Austria; and NovaBay Pharmaceuticals, Inc., Emeryville, CA, 94608, USA. Interscience Conference on Antimicrobial Agents & Chemotherapy Medical Conference Poster E-133. Chicago, Il; September 17-20, 2011.
    • 2011 ARVO (#2063) – K.Najafi, A. Jekle, D. Debabov, S. Wilmarth, R. Jain, C. Celeri, M. Zuck, T. Shiau, C. Francavilla, E. Low and M. Anderson. Aganocide®Compounds Effective Against Ophthalmic Pathogens. Ophthalmology, Eye Institute of Marin, San Rafael, CA; and NovaBay Pharmaceuticals, Inc., Emeryville, CA 94608. The Association for Research in Vision and Ophthalmology (poster 2063).
    • 2011 SC URO - S. A. Rani, C. Celeri, L. Friedman, D. Debabov, R. Najafi, M. Anderson. NVC-422 Prevents Urinary Catheter Blockage and Encrustation. NovaBay Pharmaceuticals, Inc., Emeryville, CA 94608. Simon Conference: Innovating for Continence meeting (poster), Chicago, April 12-13, 2011.
    • 2011 WHS/SAWC (#GP.16) – J.R. Crew, R. Varilla, A.Rocas, L. Wang, D. Debabov, R. Najafi, and M.B. Anderson PhD. NeutroPhase® with Sorbact® Dramatically Enhances the Speed of Wound Healing. The Wound Healing Society/ Symposium on Advanced Wound Care (poster GP-16), Dallas, TX.
    • 2011 ACS (MEDI 311) - O'Mahony, D.J.R.; Francavilla, C.; Low, E.; S. Nair, Shiau, T.P.; Turtle, E.D.; Kim, B.; A. Houchin, Francis Ruado, P. Xu, Wayham, N.P.; Anderson, M.B.; Najafi, R.; Jain, R.K. "N-Chloramine Analogs as Novel, Potent, and Fast-Acting Antimicrobial Agents.", 242nd ACS National Meeting, Denver, CO.
    • 2011 ACS (MEDI 316) - Shiau, T.P.; Low, E.; Kim, B.; Turtle, E.D.; Francavilla, C.; O'Mahony, D.J.R.; Friedman, L.; D'Lima, L.; Jekle, A.; Zuck, M.; Alvarez, N.J.; M. Anderson, Najafi, R.; Jain, R.K. "Novel Sulfonyl-Polyols with Fast-Acting, Broad-Spectrum Antimicrobial Activity.", 242nd ACS National Meeting, Denver, CO.
    • 2011 ACS (MEDI 302) - Low, E.; Turtle, E.D.; O'Mahony, D.J.R.; Francavilla, C.; Kim, B.; Shiau, T.P.; Friedman, L.C.; D’Lima, L.M.; Alvarez, N.J.; P. Xu, Wayham, N.P.; Anderson, M.B.; Najafi, R.; Jain, R.K. "Novel Quaternary Ammonium Stabilized Dichloroamines as Antimicrobial Agents." MEDI 302, 242nd ACS National Meeting, Denver, CO.
    • 2011 ACS (MEDI 300) - Turtle, E.D.; Francavilla, C.; Shiau, T.P.; O'Mahony, D.J.R.; Low, E.; Kim, B.; Friedman, L.C.; Zuck, M.E.; D'Lima, L.; P. Xu, Ruado, F.; Wayham, N.P.; Anderson, M.B.; Najafi, R.; Jain, R.K. "N-Chlorooxazolidin-2-ones as Antimicrobial Agents at Neutral pH." MEDI 300, 242nd ACS National Meeting, Denver, CO.
    • 2010 ICAAC (#F1-2119) – M. Zuck, K. Hybiske, D. Debabov, M. Anderson. NVC-422: Towards Developing Preclinical Infected Tissue Models. Interscience Conference on Antimicrobial Agents and Chemotherapy. Interscience Conference on Antimicrobial Agents & Chemotherapy (poster F-2119) Boston, MA September 12-15, 2010.
    • 2010 ICAAC (#V-420) – J. Ströhle, M. Nagl, D. Debabov, K. Hybiske, M. Anderson. In Vitro Activity of N-chlorotaurine (NCT), N-Monochloro-2-2-Dimethyltaurine (NVC-612) and N,N-Dichloro-2,2-Dimethyltaurine (NVC-422) Against Influenza Viruses. Interscience Conference on Antimicrobial Agents and Chemotherapy (poster V-420) Boston, MA September 12-15, 2010.
    • 2010 IDSA (#668) – S. Ibrahim, D. Debabov, M. Ghannoum, M. Anderson, B. Memarzadeh. In vitro evaluation of the antifungal activity of NVC-422 (N,N-dichloro-2,2-dimethyltaurine) using a novel cadaver nail model. Infectious Diseases Society of America, 48th Annual Meeting (poster 668) Vancouver, BC October 21-24, 2010.
    • 2010 ARVO (#D-1029) – K. Najafi, S.S. Wilmarth, R. Najafi, B. Khosrovi, M. Anderson, C. Celeri, D. Debabov, M. Chowhan, D.W. Stroman. In vitro Microbiocidal Activity in Tears of N,N-dichloro-2,2-dimethyltaurine (NVC-422, AL-46383A), a Novel Topical Ophthalmic Agent. ARVO, Fort Lauderdale, May 2-6, 2010. The Association for Research in Vision and Ophthalmology (poster D-1029).
    • 2010 ICAAC (#K-2199) – S. A. Rani, C. Celeri, D. Debabov, R. Najafi, M. Anderson. Efficacy of NVC-422, a Novel Derivative of N-Chlorotaurine, in controlling crystalline Proteus mirabilis biofilm formation on urinary catheters. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC; poster K-2199), Boston, September 12-15, 2010.
    • 2010 ICAAC (#F1-2118) - M. Nagl, C. Martini, A. Hammerer-Lercher, M. Zuck, D. Debabov, M. Anderson Anticoagulant Effects of N-Chlorotaurine and the Analogs N-monochloro-2,2-dimethyltaurine and N,N-dichloro-2,2-dimethyltaurine. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Boston, September 12-15, 2010.
    • 2010 ASH - J. Ströhle, M. Nagl, D. Debabov, K. Hybiske, M. Anderson. Activity of N-chlorotaurine and N-chloro-dimethyltaurines against influenza viruses. Annual Conference of the Austrian Society for Hygiene, Microbiology and Preventive Medicine, Vienna, Austria, May 17-20, 2010.

    Cancer/Oncology

    • 2009 AACR #5569 - Christopher M. Pleiman, Adam Willardsen, In Chul Kim, Warren S. Weiner, Chad Bradford, Bruce Roth, Harry Austin, Robert J. Halter, Chris Jolley, Gary Mather, Kenton Zavitz, Mark Anderson, Joshua Jones and Robert O. Carlson. Characterization of an orally bioavailable homolog of MPC-6827 (MPI-443803) that maintains high brain penetration. AACR 100th Meeting April 18-22, 2009. Denver, CO. Poster #5569.
    • 2009 AACR #2706 - Nilantha Sirisoma, Azra Pervin, Hong Zhang, Songchun Jiang, J. Adam Willardsen, Mark B. Anderson, Gary Mather, Christopher M. Pleiman, Shailaja Kasibhatla, Ben Tseng, John Drewe, Sui Xiong Cai. Discovery of N-(4-Methoxyphenyl)-N,2-dimethylquinazolin-4-amine, MPC-6827, a Potent Apoptosis Inducer and Efficacious Anticancer Agent with High Blood Brain Barrier Penetration. AACR 2009 Abstract #2706 March 30, 2009.
    • 2008 ACS MEDI-101 - Cai, Sui Xiong; Sirisoma, Nilantha; Pervin, Azra; Zhang, Hong; Jiang, Songchun; Baichwal, Vijay; Willardsen, J. Adam; Anderson, Mark; Pleiman, Christopher M.; Tseng, Ben; Kasibhatla, Shailaja; Drewe, John. Discovery of 2-Chloro-N-(4-Methoxyphenyl)-N-Methylquinazolin-4-Amine (EP128265, MPI-0441138) as A Potent Apoptosis Inducer Using Anticancer Screening Apoptosis Program (ASAP), A Cell- and Caspase-Based Platform. Abstracts of Papers, 235th ACS National Meeting, New Orleans, LA, United States, April 6-10, 2008 (2008), MEDI-101.
    • 2008 AACR #1265 - Nilantha Sirisoma, Azra Pervin, Hong Zhang, Songchun Jiang, Vijay Baichwal, J. Adam Willardsen, Mark Anderson, Christopher M. Pleiman, Ben Tseng, Shailaja Kasibhatla, John Drewe, Sui Xiong Cai. 2-Chloro-N-(4-Methoxyphenyl)-N-Methylquinazolin-4-Amine (Ep128265, Mpi-0441138) as An Inducer of Apoptosis with In vivo Activity. AACR April 12-16, 2008, San Diego, California, 99th Meeting Abstract # 1265.
    • 2001 APS - Haitao Li, Quyen-Quyen Do, Yufeng Hong, Eileen Tompkins, Ved Pathak, Lance Christie, David Luthin, Genevieve Paderes, Haresh Vazir, and Mark B Anderson. Discovery and Optimization of Potent Small Molecule Gnrh (Gonadotropin Releasing Hormone) Antagonists 4th Australia Peptide Symposium Poster Oct 7-12 2001.

    Pulmonary, Cardiovascular & Asthma

    • 1996 IMCS - Anderson, M. B., Kilgore, K, From the Pharaoh's Tomb to the Pharmacy. International Medicinal Chemistry Symposium Poster, September 1996.
    • 1996 ACS - Anderson, M.B., Lucchesi, B.R., Kilgore, K.S., et al Glycomimetics and Granulomatous Vasculitis. ACS Pacific Regional Conference, San Francisco, October 1996.
    • 1994 XVIItH ICS - B. N. Narasinga Rao, M. B. Anderson, J. H. Musser, J. H. Gilbert, M. E. Schaefer, C. Foxall and B. K. Brandley, Identification of Novel Selectin Inhibitors Using Slex Pharmacophore Based Search. XVIIth International Carbohydrate Symposium, July 17‑22, 1994, Ottawa, Canada.
    • 1994 IISTS - B. K. Brandley, N. Rao, M. B. Anderson, H. Lopez, Strategies For The Design and Use of Carbohydrates and Their Derivatives as Anti‑Inflammatory Therapeutics. Immunological Implications of Shock, Trauma and Sepsis in Munich, March 2‑6, 1994.
    Presentations

    Infectious Disease & Medical Devices

    • 2012 R. Bryan Miller Symposium, March 15-16 at UC Davis Department of Chemistry. Invited speaker on “Hydrogel Drug Delivery for the Treatment of Impetigo”. http://www.chem.ucdavis.edu/miller see http://blueline.ucdavis.edu/MillerSymposium/MillerFlyer2012FINAL.pdf
    • NeutroPhase® Product Launch (vendor booth) and presentation assistance at the Symposium on Advanced Wound Care (SAWC), Las Vegas, NV; October 13 – 15, 2011.
    • Mark B. Anderson, Ph.D. Infectious disease invited talk on Impetigo at the Cambridge Healthtech Institute (CHI) Conference; San Diego, CA 2011.
    • Mark B. Anderson, Ph.D. Infectious disease invited talk on Impetigo at the 3rd Anti-Infectives Summit (IQPC/AIS); The Westin Philadelphia, PA; January 24 – 26, 2011 http://www.iqpc.com/Event.aspx?id=395482
    • Mark B. Anderson, Ph.D. Invited panel discussion on Corporate Collaborations & Partners at the 3rd Anti-Infectives Summit (IQPC/AIS); The Westin Philadelphia, PA; January 24 – 26, 2011.
    • Notable People in R&D. Article of one of nine people recognized in the February issue of "R&D Directions" for the top noteworthy 2010 leaders who have made lasting contributions in research; Notable People in R&D, February issue page 16 2011. http://www.pharmalive.com/magazines/randd/
    • Mark Anderson commentary in Scientific American Magazine about Nice Germs Finish Last: "Good Samaritan" Bacteria Provide New Clues in Antibiotic Resistance - Resistant. Bacteria help their kin survive antibiotics, but at a cost. By Melinda Wenner Moyer. November 2, 2010. The findings could spur scientists to develop better antibiotics. If indole allows pathogenic bacteria to withstand antibiotics, it may be possible to thwart drug resistance by blocking indole signaling with small molecules, Collins says. Alternatively, "the findings suggest the possibility that scientists could one day use indole or an indole-based therapeutic, if proven safe, to help beneficial bacteria outcompete pathogenic bacteria in the urinary tract or intestinal system," says Mark Anderson, Chief Scientific Officer of Emeryville, Calif.-based Nova­Bay Pharmaceuticals, which develops drugs for antibiotic-resistant infections. See http://www.scientificamerican.com/article.cfm?id=nice-germs-finish-last

    Neurodegeneration/Neurology

    • Anderson, Mark B. Invited Lecture on Alzhiemer’s Disease Pathology, Agents and Actions Targeting Amyloid for the Purdue University Special Topics Symposium. October 5th, 2007, West Lafayette, Indiana.

    Neuroendocrine/Oncology

    • Mark Anderson invited toxicology presentation: M. Anderson*, V. Pathak, Y. Hong, L. Christie, R. Rajapakse, Q. Do, H. Li, E. Tompkins, J. Feng, D. Luthin, K. Nareed-Hood, M. Castro, S. Barnum , J. May, E. Iatsimirskaia, M. Gregory, Kenna Anderes, R. Castillo, G. Paderes. The Power of Parallel Medicinal Chemistry in Drug Discovery - An Illustration. Society of Toxicology, Irvine, CA 6 June 2000.
    • Mark Anderson invited Combinatorial Chemistry Symposium: M. B. Anderson*, V. Pathak, Y. Hong, L. Christie, R. Rajapakse, Q. Do, H. Li, E. Tompkins, J. Feng, D. Luthin, K. Nareed-Hood, M. Castro, S. Barnum , J. May, E. Iatsimirskaia, M. Gregory, Kenna Anderes, R. Castillo, G. Paderes. The Power of Medicinal & Combinatorial Chemistries in Drug Discovery - An Illustration. UCSD San Diego Combinatorial Chemistry Symposium, CA 13 July 2001.

    Pulmonary, Cardiovascular & Asthma

    • Anderson*, M.B., Lucchesi, B.R., Kilgore, K.S., et al., Inhibitors of Selectin-Mediated Cell Adhesion. New Frontiers in Cardiovascular Research, International Society for Heart Research (ISHR) XX Annual Meeting, University of Michigan, Ann Arbor, Michigan August 9-12, 1998.
    • Powers, K.L., Kilgore, K.S., Anderson, M.B., Warren, J.S. Structural Analysis of Glycomimetic Inhibitors of P-Selectin-Mediated Neutrophil Adhesion. New Frontiers in Cardiovascular Research, International Society for Heart Research (ISHR) XX Annual Meeting, University of Michigan, Ann Arbor, Michigan August 9-12, 1998. See Journal of Molecular and Cellular Cardiology, 1998, 30(7), A233 poster 2.
    • Lucchesi, B.R., Kilgore, K.S., Anderson, M.B., et al Reduction of Myocardial Infarct Size in vivo By Glycomimetics. American Heart Association (AHA) San Diego, CA 1997.
    • Mark Anderson Pathology, Pharmacology and Medicinal Chemistry presentations on cell adhesion and new in vivo pulmonary model related to cell adhesion events. Sankyo Co., Tokyo, Japan.
    • Mark Anderson and Ken Kilgore Pharmacology presentations on cell adhesion and new in vivo pulmonary model related to cell adhesion events. Sankyo Co., Tokyo, Japan.
    • Anderson, M. B., Glycomimetic Inhibitors of Selectins. Targeting Cell Adhesion Molecules for Therapeutic Application. Sheraton Society Hill Hotel Philadelphia, PA. International Business Communications (IBC). December 1‑2, 1994.

     

    .....

    Patents & Published Applications

    • 2012 – US 8258145. Method of treating brain cancer. Inventor: Sui Xiong Cai, Mark B Anderson, Adam Willardsen, Nilantha Sudath Sirisoma. Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs, and in particular to the use of these compounds in treating brain cancer.
    • 2012 – US Application 20120225873. Rachel Slade, Yevgeniya Klimova, Robert J Halter, Ashantai J Yungai, Warren S Weiner, Ruth J Walton, Jon Adam Willardsen, Mark B Anderson, Kenton Zavitz. Compounds for Alzheimer's disease
    • 2012 – US 8217073. Warren S. Weiner, Rachel M. Slade, Yevgeniya I. Klimova, Ruth J. Walton, Mark B. Anderson. Pyrrole derivatives as therapeutic compounds. Avstract: Novel pyrrole derivatives are disclosed as Aβ42-lowering agents for the treatment and prevention of neurodegenerative disorders characterized by the formation or accumulation of amyloid plaques comprising the Aβ42 peptide.
    • 2011 – Application number: 13/019,963; Publication number: US 2011/0190392 A1; Filing date: Feb 2, 2011. Inventors: Azar Najafi, Bahram Memarzadeh, Sarah A. Ibrahim, Mark Brian Anderson. Polysaccharide Based Antimicrobial Formulations. Abstract: Described herein are antimicrobial formulations or compositions comprising an N-halogenated or N,N-dihalogenated amine compound and a saccharide-based gelling agent. Methods of using such formulations, including a method of preventing or treating an infection caused by a bacterial, a microbial, a sporal, a fungal or a viral activity, are also disclosed.
    • 2011 - Application number: 13/004,311; Publication number: US 2011/0200619 A1; Filing date: Jan 11, 2011. Inventors: Mark B. Anderson, In Chul Kim. Pharmaceutical Compounds as Cytotoxic Agents and Uses Thereof. Abstract: Disclosed are compounds effective as cytotoxic agents. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    • 2011 - US 7989462 . Application number: 11/773,303; Publication number: US 2008/0004297 A1; Filing date: Jul 3, 2007; Issued patent: US 7,989,462 (Issue date Aug 2, 2011). Inventors: Sui Xiong Cai, Mark B. Anderson, Adam Willardsen, Nilantha Sudath Sirisoma, Hong Zhang, Kazuyuki Suzuki. Compounds and Therapeutic Use Thereof. Abstract: Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    • 2010 - Application number: 12/780,828; Publication number: US 2010/0292255 A1; Filing date: May 14, 2010. Inventors: Ashok C. Bajji, Se-Ho Kim, Rajendra Tangallapally, Benjamin J. Markovitz, Richard Trovato, Mark B. Anderson, Daniel A. Wettstein, Mark D. Shenderovich. Therapeutic Compounds and Their Use in Treating Diseases and Disorders. Abstract: The invention provides novel therapeutic compounds, pharmaceutical compositions comprising these compounds, and methods for using these compounds and compositions to treat diseases and disorders, such as cancer.
    • 2010 - Application number: 12/794,300. Publication number: US 2010/0240630 A1. Filing date: Jun 4, 2010. Inventors: Dange Vijay KUMAR, Kraig M. Yager, David A. Gerrish, Christophe Hoarau, Mark B. Anderson. Compounds and Therapeutic Uses Thereof. Abstract: The invention relates to compounds, pharmaceutical compositions and methods useful for treating viral infection. 
    • 2010 - Application number: 12/775,253; Publication number: US 2010/0216862 A1; Filing date: May 6, 2010. Inventors: Warren S. Weiner, Rachel M. Slade, Yevgeniya I. Klimova, Ruth J. Walton, Mark B. Anderson. Novel pyrrole derivatives are disclosed as Aβ42-lowering agents for the treatment and prevention of neurodegenerative disorders characterized by the formation or accumulation of amyloid plaques comprising the Aβ42 peptide.
    • 2010 - Application number: 12/719,672; Publication number: US 2010/0184975 A1; Filing date: Mar 8, 2010. Inventors: Rachel Slade, Yevgeniya Klimova, Robert J. Halter, Ashantai J. Yungai, Warren S. Weiner, Ruth J. Walton, Jon Adam Willardsen, Mark B. Anderson, Kenton Zavitz. Compounds for Alzheimer’s Disease. The invention provides novel compounds useful for the treatment of neurodegenerative disorders including Alzheimer's disease and dementia.
    • 2010 - Application number: 12/574,632; Publication number: US 2010/0093773 A1; Filing date: Oct 6, 2009. Inventors: Mark Laughlin, Mark B. Anderson, Adam Willardsen, Chris Pleiman. Methods of Treating Cancer. Abstract: Disclosed is (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride effective as a vascular disrupting agent. (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride is useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs, and in particular to its use in treating cancer.
    • 2010 - Application number: 12/500,863; Publication number: US 2010/0069383 A1; Filing date: Jul 10, 2009. Inventors: Mark B. Anderson, J. Adam Willardsen, Warren S. Weiner, Ashantai Yungai, Robert J. Halter, Yevgeniya Klimova, Kazuyuki Suzuki, Matthew Reeder. Compounds and Therapeutical Use Thereof. Abstract: Disclosed are 4-arylamino-quinazolines and analogs thereof that are effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs. 
    • 2010 - Application number: 12/500,449; Publication number: US 2010/0068197 A1; Filing date: Jul 9, 2009. Inventors: Mark B. Anderson, J. Adam Willardsen, Warren S. Weiner, Kazuyuki Suzuki, Robert J. Halter, In Chul Kim, Matthew Reeder, Ashantai Yungai. Pharmaceutical Compounds as Inhibitors of Cell Proliferation and The Use Thereof. Abstract: Disclosed are compounds of Formula I effective as cytotoxic agents. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    • 2010 - Application number: 12/057,140; Patent number: 7714022; Filing date: Mar 27, 2008; Issue date: May 11, 2010. Inventors: Warren S. Weiner, Rachel M. Slade, Yevgeniya I. Klimova, Ruth J. Walton, Mark B. Anderson. Novel pyrrole derivatives are disclosed as Aβ42-lowering agents for the treatment and prevention of neurodegenerative disorders characterized by the formation or accumulation of amyloid plaques comprising the Aβ42 peptide.
    • 2010 - US 7842805. Application number: 11/773,293; Publication number: US 2008/0020985 A1; Filing date: Jul 3, 2007; Issued patent: US 7,842,805 (Issue date Nov 30, 2010). Inventors: Sui Xiong Cai, Mark B. Anderson, Adam Willardsen, Songchun Jiang, Robert J. Halter, Rachel Slade, Yevgeniya Klimova. Pharmaceutical Compounds as Activators of Caspases and Inducers of Apoptosis. Abstract: Disclosed are 1-arylamino-phthalazines, 4-arylamino-benzo[d][1,2,3]triazines, and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    • 2010 – US 7678823. Application number: 11/696,526; Publication number: US 2008/0249135 A1; Filing date: Apr 4, 2007; Issued patent: US7678823 (Issue date Mar 16, 2010). Inventors: Rachel Slade, Yevgeniya Klimova, Robert J. Halter, Ashantai J. Yungai, Warren S. Weiner, Ruth J. Walton, Jon Adam Willardsen, Mark B. Anderson, Kenton Zavitz. Compounds for Alzheimer’s Disease. Abstract: The invention provides novel compounds useful for the treatment of neurodegenerative disorders including Alzheimer's disease and dementia.
    • 2009 - Application number: 12/422,767; Publication number: US 2009/0275583 A1; Filing date: Apr 13, 2009. Kraig Yager, In Chul Kim, Michael Saunders, David Gerrish, Dange Vijay Kumar, Mark B. Anderson. Antiviral Compounds and Use Thereof. Abstract: The invention relates ot compounds, pharmaceutical compositions and methods useful for treating viral infections.
    • 2009 - Application number: 11/993,519; Publication number: US 2009/0149429 A1; Filing date: Jun 22, 2006. Inventors: Esther Arranz Plaza, Kraig M. Yager, David Allen Gerrish, Mark B. Anderson, In Chul Kim, Dange Vijay Kumar. Antiviral Compounds. Abstract: The invention relates to compounds, pharmaceutical compositions and methods useful for treating viral infection.
    • 2009 - Application number: 11/748,362; Patent number: 7595401; Filing date: May 14, 2007; Issue date: Sep 29, 2009. Inventors: Ashok C. Bajji, Se-Ho Kim, Benjamin Markovitz, Richard Trovato, Rajendra Tangallapally, Mark B. Anderson, Daniel Wettstein, Mark Shenderovich, John A. Vanecko. Therapeutic compounds and their use in cancer. Abstract: The invention relates to compounds of Formula I for use in cancer.
    • 2009 - WO2009065035, PCT/US2008/083636. Inventors: Bajji, Ashok C.; Kim, Se-Ho; Tangallapally, Rajendra; Markovitz, Benjamin; Trovato, Richard; Anderson, Mark B.; Wettstein, Daniel; Shenderovich, Mark. Therapeutic Compounds and Their Use in Treating Diseases and Disorders. Abstract: The invention provides novel therapeutic compounds, pharmaceutical compositions comprising these compounds, and methods for using these compounds and compositions to treat diseases and disorders, such as cancer.
    • 2008 - R斯萊德, Rachel Slade, Y克裡莫娃, Yevgeniya Klimova, Rj霍爾特, Robert J Halter, Aj雲蓋, Ashantai J Yungai, Ws韋納, Warren S Weiner, Rj沃爾頓, Ruth J Walton, Ja維拉德森, Jon Adam Willardsen, Mb安德森, Mark B Anderson, K扎維茨, Kenton Zavitz: 用於阿爾茨海默氏病的化合物. / Compounds for alzheimer's disease.美瑞德生物工程公司Oct, 3 2008: HK 1113485
    • 2008 - Application number: 11/773,285; Publication number: US 2008/0051398 A1; Filing date: Jul 3, 2007. Inventors: Sui Ciong Cai, Mark B. Anderson, Adam Willardsen, Nilantha Sudath Sirisoma. Method of Treating Brain Cancer. Abstract: Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs, and in particular to the use of these compounds in treating brain cancer.
    • 2008 - Patent Number: 2008097341 (application serial number US2007/074478). Inventors: Kraig M. Yager, In Chul Kim, David Gerrish, Mark B. Anderson. Antiviral Compounds and Use Thereof. / Composés Antiviraux Et Leur Utilisation. The invention relates to compounds, pharmaceutical compositions and methods useful for treating viral infection. L'invention concerne des composés, des compositions pharmaceutiques et des procédés qui s'utilisent pour traiter une infection virale.
    • 2008 - CIP of PCT/US06/000056. Inventors: Cai, Sui Xiong; Anderson, Mark B.; Willardsen, Adam; Sirisoma, Nilantha Sudath; Zhang, Hong; Suzuki, Kazuyuki. Preparation of Substituted Quinazolinamines as Activators of Caspases and Inducers of Apoptosis. U.S. Pat. Appl. Publ. (2008), 50pp., Cont.-in-part of Appl. No. PCT/US06/000056. CODEN: USXXCO US 2008004297 A1 20080103 CAN 148:121727 AN 2008:12280.
    • 2007 - WO 2007095383. Inventors: Walton, Ruth J.; Slade, Rachel M.; Willardsen, J. Adam; Weiner, Warren S.; Anderson, Mark B. Prodrugs of Ph Alkanoic Acids with Enhanced Delivery To The Brain Or Across The Blood-Brain-Barrier For Treatment of Dementia. PCT Int. Appl. (2007), 56pp. CODEN: PIXXD2 WO 2007095383 A2 20070823 CAN 147:285038 AN 2007:941178. PCT/US2007/004189. Abstract: The invention relates prodrugs of phenyl alkanoic acids. The prodrugs of the invention can enhance and/or improve delivery of the phenyl alkanoic acid moiety to a desired target tissue.
    • 2007 – WO 2007076161; International PCT/US2006/049558; PCT Int. Appl. (2007). Inventors: Bajji, Ashok C.; Kim, Se-Ho; Trovato, Richard; Mchugh, Robert J.; Markovitz, Benjamin; Anderson, Mark B. Compounds with Therapeutic Activity. Composés Ayant Une Activité Thérapeutique. Abstract: Methods and pharmaceutical compositions for treating and/or delaying the onset of viral infection are provided. The pharmaceutical compositions include compounds having an oxazole core. Additionally, the compositions can be used to treat cardiovascular disorders and cancer. Abstract: L'invention concerne des procédés et des compositions pharmaceutiques pour traiter et/ou pour retarder le déclenchement d'une infection virale. Les compositions pharmaceutiques comprennent des composants ayant un noyau oxazole. En outre, les compositions peuvent être utilisées pour traiter les troubles cardiovasculaires et le cancer.
    • 2007 - WO 2007002411; International Application Number: PCT/US2006/024493. PCT Int. Appl. (2007). Inventors: Arranz Plaza, Esther; Yager, Kraig M.; Gerrish, David Allen; Anderson, Mark B.; Kim, In Chul; Kumar, Dange Vijay. Antiviral Compounds. Abstract: The invention relates to compounds, pharmaceutical compositions and methods useful for treating viral infection.
    • 2007 – Canadian Patent CA 2609280; C07J 53/00; A61K 31/56; Application date: 2006-06-22; Publication date: 2007-01-04. Inventors: Arranz Plaza, Esther; Yager, Kraig M.; Gerrish, David Allen; Anderson, Mark B.; Kim, In Chul; Kumar, Dange Vijay. Antiviral Compounds. Abstract: The invention relates to compounds, pharmaceutical compositions and methods useful for treating viral infection.
    • 2009 - EP2038041 (A2). Inventors: Bajji Ashok C; Kim Se-Ho; Markovitz Benjamin; Trovato Richard; Tangallapally Rajendra; Anderson Mark B; Wettstein Daniel; Shenderovich Mark; Vanecko John A. Therapeutic compounds and their use in cancer.
    • 2007 - WO 2007134298. Inventors: Bajji Ashok C; Kim Se-Ho; Markovitz Benjamin; Trovato Richard; Tangallapally Rajendra; Anderson Mark B; Wettstein Daniel; Shenderovich Mark; Vanecko John A. Therapeutic compounds and their use in cancer.
    • 2007 - Patent Number: 2007134298; Date: 20071122. Inventors: Bajji, Ashok; Kim, Se-Ho; Markovitz, Benjamin; Trovato, Richard; Tangallapally, Rajendra; Anderson, Mark B.; Wettstein, Daniel; Shenderovich, Mark; Vanecko, John A.Therapeutic Compounds and Their Use in Cancer. Composés Thérapeutiques et Leur Utilisation Contre le Cancer. Abstract: The invention relates to compounds of Formulae I-III and their therapeutic uses. La présente invention concerne des composés répondant aux formules (I) à (III) et leurs utilisations thérapeutiques.
    • 2007 - US 20070299258. Inventors: Bajji, Ashok C.; Kim, Se-Ho; Markovitz, Benjamin; Trovato, Richard; Tangallapally, Rajendra; Anderson, Mark B.; Wettstein, Daniel; Shenderovich, Mark; Vanecko, John A. Preparation of Substituted Purinamines as Antitumor Agents. PCT Int. Appl. (2007), 477pp. CODEN: PIXXD2 WO 2007134298 A2 20071122 CAN 148:11252 AN 2007:1332992. PCT/US2007/068899. Abstract: Compounds of the formula (I) (II) (III) in which A is chosen from a substituted or unsubstituted aryl, heteroaryl, heterocyclic, or carbocyclic group. B is chosen from a substituted or unsubstituted aryl, heteroaryl, heterocyclic, or carbocyclic group Rl is chosen from hydro, alkyl, aryl, heteroaryl, amino, halo, sulfur, and thioalkyl.
    • 2007 - WO 2007134298. Inventors: Bajji, Ashok C.; Kim, Se-Ho; Markovitz, Benjamin; Trovato, Richard; Tangallapally, Rajendra; Anderson, Mark B.; Wettstein, Daniel; Shenderovich, Mark; Vanecko, John A. Preparation of Substituted Purinamines as Antitumor Agents. PCT Int. Appl. (2007), 477pp. CODEN: PIXXD2 WO 2007134298 A2 20071122 CAN 148:11252 AN 2007:1332992. PCT/US2007/068899. Abstract: Compounds of the formula (I) (II) (III) in which A is chosen from a substituted or unsubstituted aryl, heteroaryl, heterocyclic, or carbocyclic group. B is chosen from a substituted or unsubstituted aryl, heteroaryl, heterocyclic, or carbocyclic group Rl is chosen from hydro, alkyl, aryl, heteroaryl, amino, halo, sulfur, and thioalkyl.
    • 2007 - WO 2007038684, PCT/US2006/037903. Inventors: Weiner, Warren S.; Slade, Rachel M.; Klimova, Yevgeniya I.; Walton, Ruth J.; Anderson, Mark B. Pyrrole Derivatives as Therapeutic Compounds. Pyrrole Derivatives as Amyloid Beta 42-Lowering Agents. Their Preparation, Pharmaceutical Compositions, and Use in Therapy. PCT Int. Appl. (2007), 84pp. CODEN: PIXXD2 WO 2007038684 A2 20070405 CAN 146:379817 AN 2007:384648. PCT/US2006/037903. Abstract: Novel pyrrole derivatives are disclosed as Aβ42-lowering agents for the treatment and prevention of neurodegenerative disorders characterized by the formation or accumulation of amyloid plaques comprising the Aβ42 peptide.
    • 2007 - CA 2623558, PCT/US2006/037903. Inventors: Weiner, Warren S.; Slade, Rachel M.; Klimova, Yevgeniya I.; Walton, Ruth J.; Anderson, Mark B. Pyrrole Derivatives as Therapeutic Compounds. Pyrrole Derivatives as Amyloid Beta 42-Lowering Agents. Their Preparation, Pharmaceutical Compositions, and Use in Therapy. PCT Int. Appl. (2007), 84pp. CODEN: PIXXD2 WO 2007038684 A2 20070405 CAN 146:379817 AN 2007:384648. PCT/US2006/037903. Abstract: Novel pyrrole derivatives are disclosed as Aβ42-lowering agents for the treatment and prevention of neurodegenerative disorders characterized by the formation or accumulation of amyloid plaques comprising the Aβ42 peptide.
    • 2006 - WO 2006135383. Inventors: Bajji, Ashok; Morham, Scott; Anderson, Mark B.; McHugh, Robert J.; Trovato, Richard; Weiner, Warren S.; Kim, Se-Ho. Indazoles: Preparation of Indazoles For Treating Viral Infection and Other Diseases Mediated By Rho Kinase. PCT Int. Appl. (2006), 221pp. CODEN: PIXXD2 WO 2006135383 A2 20061221 CAN 146:62713 AN 2006:1338316. PCT/US2005/027730. Abstract: Methods and pharmaceutical compositions for treating and/or delaying the onset of viral infection are provided. The pharmaceutical compositions include compounds having an indazole core. Additionally, the compositions can be used to treat cardiovascular disorders and cancer.
    • 2006 - CA 2593005, PCT/US2006/000176. PCT Int. Appl. (2006), 97 pp. CODEN: PIXXD2 WO 2006074223 A2 20060713 CAN 145:145755 AN 2006:676927. Inventors: Cai, Sui Xiong; Anderson, Mark B.; Willardsen, Adam; Jiang, Songchun; Halter, Robert J.; Slade, Rachel; Klimova, Yevgeniya. Pharmaceutical Compounds as Activators of Caspases and Inducers of Apoptosis and The Use Thereof. Abstract: Disclosed are 1-arylamino-phthalazines, 4-arylamino-benzo[d][1,2,3]triazines, and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    • 2006 - US 20080051398. Inventors: Cai, Sui Xiong; Anderson, Mark B.; Willardsen, Adam; Sirisoma, Nilantha Sudath. Method of Treating Brain Cancer. International Application Number: PCT/US2006/000122. PCT Int. Appl. (2006), 90 pp. CODEN: PIXXD2 WO 2006074187 A2 20060713 CAN 145:145733 AN 2006:675266. 13.07.2006 A61K 39/395 PCT/US2006/000122 MYRIAD GENETICS, INC. Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs, and in particular to the use of these compounds in treating brain cancer.
    • 2006 - WO 2006074187. Inventors: Cai, Sui Xiong; Anderson, Mark B.; Willardsen, Adam; Sirisoma, Nilantha Sudath. Method of Treating Brain Cancer. International Application Number: PCT/US2006/000122. PCT Int. Appl. (2006), 90 pp. CODEN: PIXXD2 WO 2006074187 A2 20060713 CAN 145:145733 AN 2006:675266. 13.07.2006 A61K 39/395 PCT/US2006/000122 MYRIAD GENETICS, INC. Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs, and in particular to the use of these compounds in treating brain cancer.
    • 2006 - CIPO CA 2592971. Inventors: Cai, Sui Xiong; Anderson, Mark B.; Willardsen, Adam; Sirisoma, Nilantha Sudath. Method of Treating Brain Cancer. International Application Number: PCT/US2006/000122. PCT Int. Appl. (2006), 90 pp. CODEN: PIXXD2 WO 2006074187 A2 20060713 CAN 145:145733 AN 2006:675266. 13.07.2006 A61K 39/395 PCT/US2006/000122 MYRIAD GENETICS, INC. Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs, and in particular to the use of these compounds in treating brain cancer.
    • 2006 - WO 2006074147. Inventors: Cai, Sui Xiong; Anderson, Mark B.; Willardsen, Adam; Sirisoma, Nilantha Sudath; Zhang, Hong; Suzuki, Kazuyuki. Nitrogen Containing Bicyclic Compounds and Therapeutical Use Thereof. International Application Number: PCT/US2006/000056. 13.07.2006 C07D 401/00 MYRIAD GENETICS, INC. Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    • 2006 - CA 2592900. Inventors: Cai, Sui Xiong; Anderson, Mark B.; Willardsen, Adam; Sirisoma, Nilantha Sudath; Zhang, Hong; Suzuki, Kazuyuki. Nitrogen Containing Bicyclic Compounds and Therapeutical Use Thereof. International Application Number: PCT/US2006/000056. 13.07.2006 C07D 401/00 MYRIAD GENETICS, INC. Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    • 2006 - WO 2006041874, PCT/US2005/035747. Inventors: Slade, Rachel; Klimova, Yevgeniya; Halter, Robert J.; Yungai, Ashantai J.; Weiner, Warren S.; Walton, Ruth J.; Willardsen, Jon Adam; Anderson, Mark B.; Zavitz, Kenton. Compounds For Alzheimer's Disease. International Application Number: PCT/US2005/035747. PCT Int. Appl. (2006), 300 pp. CODEN: PIXXD2 WO 2006041874 A2 20060420 CAN 144:412361 AN 2006:361235. 20.04.2006 C07D 209/04 MYRIAD GENETICS, INC.
    • 2006 - CA 2582674, PCT/US2005/035747. Inventors: Slade, Rachel; Klimova, Yevgeniya; Halter, Robert J.; Yungai, Ashantai J.; Weiner, Warren S.; Walton, Ruth J.; Willardsen, Jon Adam; Anderson, Mark B.; Zavitz, Kenton. Compounds For Alzheimer's Disease. International Application Number: PCT/US2005/035747. PCT Int. Appl. (2006), 300 pp. CODEN: PIXXD2 WO 2006041874 A2 20060420 CAN 144:412361 AN 2006:361235. 20.04.2006 C07D 209/04 MYRIAD GENETICS, INC.
    • 2006 - JP 2008-515805 A (15-May-2008), PCT/US2005/035747. Inventors: Slade, Rachel; Klimova, Yevgeniya; Halter, Robert J.; Yungai, Ashantai J.; Weiner, Warren S.; Walton, Ruth J.; Willardsen, Jon Adam; Anderson, Mark B.; Zavitz, Kenton. Compounds For Alzheimer's Disease. International Application Number: PCT/US2005/035747. PCT Int. Appl. (2006), 300 pp. CODEN: PIXXD2 WO 2006041874 A2 20060420 CAN 144:412361 AN 2006:361235. 20.04.2006 C07D 209/04 MYRIAD GENETICS, INC.
    • 2006 - US 7101878, WO00/20358. Inventors: Anderson, Mark Brian; Vazir, Haresh N.; Luthin, David Robert; Paderes, Genevieve Deguzman; Pathak, Ved P.; Christie, Lance Christopher; Hong, Yufeng; Tompkins, Eileen Valenzuela; Li, Haitao; Faust, James. Non-Peptide Gnrh Agents, Methods and Intermediates For Their Preparation. PCT/US2007/068899. Also see Appl. No. 9/763,216. PCT Filed Aug. 20, 1999, PCT No. PCT/US99/18790 § 371(c)(1), (2), (4) Date Feb. 20, 2001, PCT Pub. No. WO00/20358, PCT Pub. Date Apr. 13, 2000. Abstract: Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. Such compounds and their pharmaceutically acceptable salts, multimers, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described.
    • 2006 - WO 20040010033 (2004), WO00/20358. Inventors: Anderson, Mark Brian; Vazir, Haresh N.; Luthin, David Robert; Paderes, Genevieve Deguzman; Pathak, Ved P.; Christie, Lance Christopher; Hong, Yufeng; Tompkins, Eileen Valenzuela; Li, Haitao; Faust, James. Non-Peptide GnRH Agents, Methods and Intermediates For Their Preparation. PCT/US2007/068899. Also see Appl. No. 9/763,216. PCT Filed Aug. 20, 1999, PCT No. PCT/US99/18790 § 371(c)(1), (2), (4) Date Feb. 20, 2001, PCT Pub. No. WO00/20358, PCT Pub. Date Apr. 13, 2000. Abstract: Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. Such compounds and their pharmaceutically acceptable salts, multimers, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described.
    • 2006 - WO 2006074187. Inventors: Cai, Sui Xiong; Anderson, Mark B.; Willardsen, Adam; Sirisoma, Nilantha Sudath. Preparation of 4-Arylamino-Quinazolines and Analogs as Activators of Caspases and Inducers of Apoptosis. PCT Int. Appl. (2006), 90 pp. CODEN: PIXXD2 WO 2006074187 A2 20060713 CAN 145:145733 AN 2006:675266.
    • 2005 - WO 20050250846, USPTO Application: 20050250846. Inventors: Mark B. Anderson, Lance Christopher Christie, Quyen-Quyen Thuy Do, Yufeng Hong, Haitao Li, Ranjan Jagath Rajapakse, Eric T. Sun, Eileen Valenzuela Tompkins, Jun Feng, Ved P. Pathak. Non-Peptide GnRH Agents, Pharmaceutical Compositions and Methods For Their Use. Abstract: Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. Such compounds and their pharmaceutically acceptable salts, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described.
    • 2005 - US 6903132. Inventors: Anderson, Mark B.; Christie, Lance Christopher; Do, Quyen-Quyen Thuy; Feng, Jun; Hong, Yufeng; Li, Haitao; Pathak, Ved P.; Rajapakse, Ranjan Jagath; Sun, Eric T.; Tompkins, Eileen Valenzuela. Non-Peptide GnRH Agents, Pharmaceutical Compositions and Methods For Their Use. Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. Such compounds and their pharmaceutically acceptable salts, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described.
    • 2004 - US 20040053951. Inventors: Christie, Lance C.; Anderson, Mark B.; Feng, Jun; Hong, Yufeng; Pathak, Ved P.; Rajapakse, Ranjan J.; Tompkins, Eileen V.; Vazir, Haresh; Li, Haitao. Non-Peptide GnRH Agents, Pharmaceutical Compositions, and Methods For Their Use. Pfizer Inc. No. 10364193 filed on 02/11/2003. Abstract: Non-peptide GnRH agents that inhibit the effect of gonadotropin-releasing hormone are described. Such agents are useful for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. United States Application 20040053951 A1.
    • 2004 - US 20040014787. Inventors: Mark B. Anderson; Lance Christopher Christie, Ballwin; Quyen-Quyen Thuy Do; Jun Feng; Yufeng Hong, San; Haitao Li, San Diego; Ved P. Pathak, San Diego; Ranjan Jagath Rajapakse; Eric T. Sun, San; Eileen Valenzuela Tompkins. US 20040014787A1. 2004/0014787 Al. Non-Peptide GnRH Agents, Pharmaceutical Compositions and Methods For Their Use. Agouron Pharmaceuticals, Inc. Appl. No.: 10/459,364. Filed: Jun. 11, 2003 Related U.S. Application Data. Provisional application No. 60/388,788, filed on Jun. 13, 2002. Abstract: Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. Such compounds and their pharmaceutically acceptable salts, pro- drugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone- dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described.
    • 2004 - US 6833372. Inventors: Christie, Lance C.; Anderson, Mark B.; Feng, Jun; Hong, Yufeng; Pathak, Ved P.; Rajapakse, Ranjan J.; Tompkins, Eileen V.; Vazir, Haresh; Li, Haitao. Non-Peptide GnRH Agents, Pharmaceutical Compositions, and Methods For Their Use. Pfizer Inc. No. 10364193 filed on 02/11/2003 Non-peptide GnRH agents that inhibit the effect of gonadotropin-releasing hormone are described. Such agents are useful for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated.
    • 2003 - WO 2003106446. Inventors: Anderson, Mark Brian; Christie, Lance Christopher; Do, Quyen-Quyen Thuy; Feng, Jun; Hong, Yufeng; Li, Haitao; Pathak, Ved Prakash; Rajapakse, Ranjan Jagath; Sun, Eric Tak On; Tompkins, Eileen Valenzuela. Non-Peptide GnRH Agents, Pharmaceutical Compositions and Methods For Their Use. (Preparation of Furancarbonylhydrazines as Inhibitors of Gonadotropin-Releasing Hormone.) 24.12.2003 A61K 31/341 PCT/IB2003/002379 PFIZER INC. PCT Int. Appl. (2003), 115 pp. CODEN: PIXXD2 WO 2003106446 A1 20031224 CAN 140:42021 AN 2003:1006973. Methods for synthesizing the compounds and intermediates useful in their preparation are also described.
    • 2003 - CA 2489252. Inventors: Anderson, Mark Brian; Christie, Lance Christopher; Do, Quyen-Quyen Thuy; Feng, Jun; Hong, Yufeng; Li, Haitao; Pathak, Ved Prakash; Rajapakse, Ranjan Jagath; Sun, Eric Tak On; Tompkins, Eileen Valenzuela. Non-Peptide GnRH Agents, Pharmaceutical Compositions and Methods For Their Use. (Preparation of Furancarbonylhydrazines as Inhibitors of Gonadotropin-Releasing Hormone.) 24.12.2003 A61K 31/341 PCT/IB2003/002379 PFIZER INC. PCT Int. Appl. (2003), 115 pp. CODEN: PIXXD2 WO 2003106446 A1 20031224 CAN 140:42021 AN 2003:1006973. Methods for synthesizing the compounds and intermediates useful in their preparation are also described.
    • 2003 - WO 2003068769. Inventors: Christie, Lance; Anderson, Mark, Brian; Feng, Jun; Hong, Yufeng; Pathak, Ved, Prakash; Rajapakse, Ranjan, Jagath; Tompkins, Eileen, Valenzuela; Vazir, Haresh; Li, Haitao. Non-Peptide Compounds Affecting The Action of Gonadotropin-Releasing Hormone (GnRH). International Application Number: 21.08.2003 C07D 405/12 PCT/IB2003/000316 PFIZER INC. Non-peptide GnRH agents that inhibit the effect of gonadotropin-releasing hormone are described. Such agents are useful for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. The compound have the following structure: (Formula I). Non-peptide GnRH agents, pharmaceutical compositions, and methods for their use.
    • 2003 - CA 2418712 of US 6,833,372. Inventors: Christie, Lance; Anderson, Mark, Brian; Feng, Jun; Hong, Yufeng; Pathak, Ved, Prakash; Rajapakse, Ranjan, Jagath; Tompkins, Eileen, Valenzuela; Vazir, Haresh; Li, Haitao. Non-Peptide Compounds Affecting The Action of Gonadotropin-Releasing Hormone (GnRH). International Application Number: 21.08.2003 C07D 405/12 PCT/IB2003/000316 PFIZER INC. Non-peptide GnRH agents that inhibit the effect of gonadotropin-releasing hormone are described. Such agents are useful for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. The compound have the following structure: (Formula I). Agents et compositions pharmaceutiques non peptidiques anti-gnrh et methodes d'utilisation.
    • 2003 - US 6,670,167, US 20030235899 (2003). Inventors: Chen, Ping; Anderson, Mark; Deng, Ya-Li; Gaur, Smita; Kan, Chen Chen; Luo, Chun; Lundgren, Karen; Margosiak, Stephen; Nguyen, Binh; O'Connor, Patrick; Register, James; Russell, Anna Tempczyk; Sarup, Jay. Catalytic Domain of The Human Effector Cell Cycle Checkpoint Protein Kinase CHK1 Materials and Methods For Identification of Inhibitors Thereof. The present invention relates to the identification, isolation and purification of the catalytic domain of the human effector checkpoint protein kinase (hCHK1). A 1.7Å crystal structure of the hChk1 kinase domain in the active conformation is reported herein. The kinase domain of hChk1 and its associated crystal structure is described for use in the discovery, identification and characterization of inhibitors of hChk1. This structure provides a three-dimensional description of the binding site of the hChk1 for structure-based design of small molecule inhibitors thereof as therapeutic agents. Inhibitors of hChk1 find utility in the treatment of hyperproliferative disorders such as HIV and cancer.
    • 2003 - EP 1096014 (2001). Inventors: Chen, Ping; Anderson, Mark; Deng, Ya-Li; Gaur, Smita; Kan, Chen Chen; Luo, Chun; Lundgren, Karen; Margosiak, Stephen; Nguyen, Binh; O'Connor, Patrick; Register, James; Russell, Anna Tempczyk; Sarup, Jay. Catalytic Domain of The Human Effector Cell Cycle Checkpoint Protein Kinase CHK1 Materials and Methods For Identification of Inhibitors Thereof. The present invention relates to the identification, isolation and purification of the catalytic domain of the human effector checkpoint protein kinase (hChk1). A 1.7Å crystal structure of the hChk1 kinase domain in the active conformation is reported herein. The kinase domain of hChk1 and its associated crystal structure is described for use in the discovery, identification and characterization of inhibitors of hChk1. This structure provides a three-dimensional description of the binding site of the hChk1 for structure-based design of small molecule inhibitors thereof as therapeutic agents. Inhibitors of hChk1 find utility in the treatment of hyperproliferative disorders such as HIV and cancer.
    • 2003 - US 6646137. Inventors: Anderson, Mark Brian; Polinsky, Alexander; Hong, Yufeng; Gregor, Vlad Edward. Non-Peptide GnRH Agents. Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are of the following general formula, where X1, X2, Y, and Z are defined variables: STR1 Such compounds and their pharmaceutically acceptable salts, multimers, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described.
    • 2003 - EP 1334972. Inventors: Anderson, Mark B.; Christie, Lance C.; Feng, Jun; Hong, Yufeng; Li, Haitao; Pathak, Ved P.; Rajapakse, Ranjan; Tompkins, Eileen; Vazir, Haresh N. Preparation of Non-Peptide Compounds Affecting The Action of Gonadotropin-Releasing Hormone (GnRH). International Application Number: Eur. Pat. Appl. (2003), 1 p. CODEN: EPXXDW EP 1334972 A1 20030813 CAN 139:179968 AN 2003:626431.
    • 2002 - WO 2002098363. Inventors: Sun, Eric T.; Anderson, Mark B.; Anderes, Kenna L.; Christie, Lance C.; Do, Quyen-Quyen T.; Feng, Jun; Goetzen, Thomas; Hong, Yufeng; Iatsimirskaia, Eugenia A.; Li, Haitao; Luthin, David R.; Paderes, Genevieve D.; Pathak, Ved P.; Rajapakse, Ranjan Jagath; Shackelford, Scott; Tompkins, Eileen Valenzuela; Truesdale, Larry K.; Vazir, Haresh. Non-Peptide Furanyl GnRH Agents, Pharmaceutical Compositions and Methods For Their Use, and Processes For Preparing Them and Their Intermediates. PCT Int. Appl. (2002), 243 pp. CODEN: PIXXD2 WO 2002098363 A2 20021212 CAN 138:24635 AN 2002:946059. PCT/US2002/017846. Abstract: Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. Such compounds and their pharmaceutically acceptable salts, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described.
    • 2002 - CA 2449843. Inventors: Sun, Eric T.; Anderson, Mark B.; Anderes, Kenna L.; Christie, Lance C.; Do, Quyen-Quyen T.; Feng, Jun; Goetzen, Thomas; Hong, Yufeng; Iatsimirskaia, Eugenia A.; Li, Haitao; Luthin, David R.; Paderes, Genevieve D.; Pathak, Ved P.; Rajapakse, Ranjan Jagath; Shackelford, Scott; Tompkins, Eileen Valenzuela; Truesdale, Larry K.; Vazir, Haresh. Non-Peptide Furanyl Gnrh Agents, Pharmaceutical Compositions and Methods For Their Use, and Processes For Preparing Them and Their Intermediates. PCT Int. Appl. (2002), 243 pp. CODEN: PIXXD2 WO 2002098363 A2 20021212 CAN 138:24635 AN 2002:946059. PCT/US2002/017846. Abstract: Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. Such compounds and their pharmaceutically acceptable salts, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described.
    • 2001 – US 6,218,426 (2001). Inventors: Anderson, Mark; Polinsky, Alexander; Hong, Yufeng; Gregor, Vlad. Non-Peptide GnRH Agents 10.09.1999 C07C 279/12 PCT/US1999/004457. PCT Int. Appl. (1999), 90 pp. CODEN: PIXXD2 WO 9944987 A1 19990910 EP1068178, WO09944987. CA2322444 CAN 131:214183 AN 1999:576906 AGOURON PHARMACEUTICALS, INC. Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are of general formula (I), where X1, X2, Y, and Z are defined variables. Such compounds and their pharmaceutically acceptable salts, multimers, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described.
    • 2001 – WO 1999/044987 (1999). Inventors: Anderson, Mark; Polinsky, Alexander; Hong, Yufeng; Gregor, Vlad. Non-Peptide GnRH Agents 10.09.1999 C07C 279/12 PCT/US1999/004457. PCT Int. Appl. (1999), 90 pp. CODEN: PIXXD2 WO 9944987 A1 19990910 EP1068178, WO09944987. CA2322444 CAN 131:214183 AN 1999:576906 AGOURON PHARMACEUTICALS, INC. Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are of general formula (I), where X1, X2, Y, and Z are defined variables. Such compounds and their pharmaceutically acceptable salts, multimers, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described.
    • 2000 - US 7,101,878. Inventors: Anderson, Mark Brian; Vazir, Haresh N.; Luthin, David Robert; Paderes, Genevieve Deguzman; Pathak, Ved P.; Christie, Lance Christopher; Hong, Yufeng; Tompkins, Eileen Valenzuela; Li, Haitao; Faust, James. Non-Peptide GnRH Agents, Methods and Intermediates For Their Preparation. PCT Int. Appl. (2000), 444 pp. CODEN: PIXXD2 WO 2000020358 A2 20000413 CAN 132:279106 AN 2000:241135.
    • 2000 - WO 2000020358. Inventors: Anderson, Mark Brian; Vazir, Haresh N.; Luthin, David Robert; Paderes, Genevieve Deguzman; Pathak, Ved P.; Christie, Lance Christopher; Hong, Yufeng; Tompkins, Eileen Valenzuela; Li, Haitao; Faust, James. Non-Peptide GnRH Agents, Methods and Intermediates For Their Preparation. PCT Int. Appl. (2000), 444 pp. CODEN: PIXXD2 WO 2000020358 A2 20000413 CAN 132:279106 AN 2000:241135.
    • 2000 - EP1105120 (2000). Inventors: Anderson, Mark Brian; Vazir, Haresh N.; Luthin, David Robert; Paderes, Genevieve Deguzman; Pathak, Ved P.; Christie, Lance Christopher; Hong, Yufeng; Tompkins, Eileen Valenzuela; Li, Haitao; Faust, James. Non-Peptide GnRH Agents, Methods and Intermediates For Their Preparation. PCT Int. Appl. (2000), 444 pp. CODEN: PIXXD2 WO 2000020358 A2 20000413 CAN 132:279106 AN 2000:241135.
    • 1999 - WO 9929705. Inventors: Anderson, Mark B.; Kobayashi, Yoshiyuki; Itoh, Kazuhiro; Holme, Kevin R.; Cui, Jingrong; Fugedi, Peter; Peto, Csaba F.; Wang, Li; Vazir, Harish. Preparation of Sialyl Lewisx and Sialyl Lewisa Glycomimetics as Selectin Inhibitors. PCT Int. Appl. (1999), 184 pp. CODEN: PIXXD2 WO 9929705 A2 19990617 CAN 131:45047 AN 1999:390408.
    • 1999 - WO 9944987. Inventors: Anderson, Mark; Polinsky, Alexander; Hong, Yufeng; Gregor, Vlad. Preparation of N-(Hetero) Aroyl-N-(Guanidinomethylarylmethyl)-N-[(Poly)Cyclylmethyl)]Amines as Non-Peptide Gonadotropin Releasing Hormone Inhibitors. PCT Int. Appl. (1999), 90 pp. CODEN: PIXXD2 WO 9944987 A1 19990910 CAN 131:214183 AN 1999:576906.
    • 1999 - WO 9929706. Inventors: Anderson, Mark B.; Levy, Daniel E.; Holme, Kevin R. Preparation of Disalicylate Analog Based Sialyl Lewisx Mimetics as Antiinflammatory Agents and Selectin Receptors. PCT Int. Appl. (1999), 104 pp. CODEN: PIXXD2 WO 9929706 A2 19990617 CAN 131:45048 AN 1999:390409.
    • 1999 - US 6,218,426. Inventors: M. B. Anderson, A. Polinsky, Y. Hong, Vlad. E. Gregor. Non-Peptide GnRH Agents.
    • 1999 - EP1068178. Inventors: M. B. Anderson, A. Polinsky, Y. Hong, Vlad. E. Gregor. Non-Peptide GnRH Agents.
    • 1999 - WO09944987. Inventors: M. B. Anderson, A. Polinsky, Y. Hong, Vlad. E. Gregor. Non-Peptide GnRH Agents.
    • 1999 - CA2322444. Inventors: M. B. Anderson, A. Polinsky, Y. Hong, Vlad. E. Gregor. Non-Peptide GnRH Agents.
    • 1998 - US CIP of US 5837689. Inventors: Anderson, Mark B.; Levy, Daniel E.; Tang, Peng Cho; Musser, John H.; Rao, Narasinga. Preparation of Sialyl Lewisx Mimetics Containing Naphthyl Backbones as Selectin Inhibitors. U.S. (1998), 48 pp., Cont.-in-part of U. S. Ser. No. 446,185. CODEN: USXXAM US 5837689 A 19981117 CAN 130:14166 AN 1998:752223.
    • 1998 - US CIP of US 5789385. Inventors: Anderson, Mark B.; Levy, Daniel E.; Tang, Peng Cho; Musser, John H.; Rao, Narasinga; Cui, Jing Rong. Preparation of Sialyl Lewisx Mimetics Containing Phenyl Backbones as Selectin Inhibitors. U.S. (1998), 55 pp. Cont.-in-part of U.S. Ser. No. 446,185. US 5789385 A 19980804 CAN 129:161815 AN 1998:534879.
    • 1998 - US 5837690. Inventors: B. N. Narasinga Rao, M.B. Anderson, and J. H. Musser. Derivatives of Triterpenoid Acids and Uses Thereof. Abstract: Derivatives of triterpenoid acids and uses thereof.: United States Patent 5837690 Abstract: Triterpenoid acid derivatives are described that exhibit dual pharmacophobic activities, specifically selectin ligand and leukotriene biosynthetic inhibitory activities, and that thus have significant applications for the treatment or prevention of certain diseases including cancer and diseases associated with the inflammatory process as well as applications for the diagnosis of disease.
    • 1998 - AU6529194. Inventors: B. N. Narasinga Rao, M.B. Anderson, and J. H. Musser. Derivatives of Triterpenoid Acids and Uses Thereof. Abstract: Derivatives of triterpenoid acids and uses thereof.: United States Patent 5837690 Abstract: Triterpenoid acid derivatives are described that exhibit dual pharmacophobic activities, specifically selectin ligand and leukotriene biosynthetic inhibitory activities, and that thus have significant applications for the treatment or prevention of certain diseases including cancer and diseases associated with the inflammatory process as well as applications for the diagnosis of disease.
    • 1998 - US 5837689. Inventors: M. B. Anderson, D. Levy, P. Tang, J. H. Musser, B. N. N. Rao. Sialyl Lewisx Mimetics Containing Naphthyl Backbones. Abstract: Mimetics containing naphthyl backbones.
    • 1998 - AU2137297. Inventors: M. B. Anderson, D. Levy, P. Tang, J. H. Musser, B. N. N. Rao. Sialyl Lewisx Mimetics Containing Naphthyl Backbones. Abstract: Mimetics containing naphthyl backbones.
    • 1998 - WO9731006. Inventors: M. B. Anderson, D. Levy, P. Tang, J. H. Musser, B. N. N. Rao. Sialyl Lewisx Mimetics Containing Naphthyl Backbones. Abstract: Mimetics containing naphthyl backbones.
    • 1998 - US 5789385. Inventors: M. B. Anderson, D. Levy, P. Tang, J. H. Musser, B. N. N. Rao, J. Cui. Sialyl Lewisx Mimetics Containing Phenyl Backbones.
    • 1998 - AU 2136597. Inventors: M. B. Anderson, D. Levy, P. Tang, J. H. Musser, B. N. N. Rao, J. Cui. Sialyl Lewisx Mimetics Containing Phenyl Backbones.
    • 1998 - WO 9730984 (1997). Inventors: M. B. Anderson, D. Levy, P. Tang, J. H. Musser, B. N. N. Rao, J. Cui. Sialyl Lewisx Mimetics Containing Phenyl Backbones.
    • 1998 - US 5763582. Inventors: B. N. Narasinga Rao, M.B. Anderson, and J. H. Musser. Derivatives of Triterpene Acids and Uses Thereof. Abstract: Triterpenoid acid derivatives are described that exhibit dual pharmacophobic activities, specifically selectin ligand and leukotriene biosynthetic inhibitory activities, and that thus have significant applications for the treatment or prevention of certain diseases including cancer and diseases associated with the inflammatory process as well as applications for the diagnosis of disease.
    • 1998 - U.S. (1998), 48 pp., Cont.-in-part of U. S. Ser. No. 446,185. US 5837689. Inventors: Anderson, Mark B.; Levy, Daniel E.; Tang, Peng Cho; Musser, John H.; Rao, Narasinga. Preparation of Sialyl Lewisx Mimetics Containing Naphthyl Backbones as Selectin Inhibitors. U.S. (1998), 48 pp., Cont.-in-part of U. S. Ser. No. 446,185. US 5837689 A 19981117 CAN 130:14166 AN 1998:752223.
    • 1998 - CIP of US 5837689. Inventors: Anderson, Mark B.; Levy, Daniel E.; Tang, Peng Cho; Musser, John H.; Rao, Narasinga. Preparation of Sialyl Lewisx Mimetics Containing Naphthyl Backbones as Selectin Inhibitors. U.S. (1998), 48 pp., Cont.-in-part of U. S. Ser. No. 446,185. CODEN: USXXAM US 5837689 A 19981117 CAN 130:14166 AN 1998:752223.
    • 1998 - CIP of US 5789385. Inventors: Anderson, Mark B.; Levy, Daniel E.; Tang, Peng Cho; Musser, John H.; Rao, Narasinga; Cui, Jing Rong. Preparation of Sialyl Lewisx Mimetics Containing Phenyl Backbones as Selectin Inhibitors. U.S. (1998), 55 pp., Cont.-in-part of U.S. Ser. No. 446,185. CODEN: USXXAM US 5789385 A 19980804 CAN 129:161815 AN 1998:534879.
    • 1998 - Patent number: 5,763,582; Filing date: Jun 6, 1995; Issue date: Jun 9, 1998. Inventors: Narasinga Rao, Mark Brian Anderson, John Henry Musser. Derivatives of Triterpenoid Acids and Uses Therof. Abstract: Triterpenoid acid derivatives are described that exhibit dual pharmacophobic activities, specifically selectin ligand and leukotriene biosynthetic inhibitory activities, and that thus have significant applications for the treatment or prevention of certain diseases including cancer and diseases associated with the inflammatory process as well as applications for the diagnosis of disease.
    • 1997 - Patent number: 5688922; Filing date: Jun 6, 1995; Issue date: Nov 18, 1997. Inventors: Narasinga Rao, Mark Brian Anderson, John Henry Musser. Substituted fucopyranosides. Abstract: 2-Chloromethyl-3-(tri-O-benzyl-.alpha.-L-C-fucopyranoside)-1-propene and methods of making the same are described. Methods of combining this substituted fucopyranose with triterpenoid acid also are described.
    • 1997 - Patent number: 5,679,644; Filing date: Jun 6, 1995; Issue date: Oct 21, 1997. Inventors: Narasinga Rao, Mark Brian Anderson, John Henry Musser. Methods of treating diseases using triterpenoid acid derivatives. Abstract: Triterpenoid acid derivatives are described that exhibit dual pharmacophobic activities, specifically selectin ligand and leukotriene biosynthetic inhibitory activities, and that thus have significant applications for the treatment or prevention of certain diseases including cancer and diseases associated with the inflammatory process as well as applications for the diagnosis of disease.
    • 1997 - WO 9731007. Inventors: Anderson, Mark B.; Levy, Daniel E.; Tang, Peng Cho; Musser, John H.; Rao, Narasinga. Preparation of Sialyl Lewisx Mimetics Containing Flavanoid Backbones as Selectin Inhibitors. PCT Int. Appl. (1997), 160 pp. CODEN: PIXXD2 19970828 CAN 127:248358 AN 1997:579729.
    • 1997 - AU 1975297. Inventors: Anderson, Mark B.; Levy, Daniel E.; Tang, Peng Cho; Musser, John H.; Rao, Narasinga. Preparation of Sialyl Lewisx Mimetics Containing Flavanoid Backbones as Selectin Inhibitors. PCT Int. Appl. (1997), 160 pp. CODEN: PIXXD2 19970828 CAN 127:248358 AN 1997:579729.
    • 1997 - WO 9731006. Inventors: Anderson, Mark B.; Levy, Daniel E.; Tang, Peng Cho; Musser, John H.; Rao, Narasinga. Preparation of Sialyl Lewisx Mimetics Containing Naphthyl Backbones as Selectin Inhibitors. PCT Int. Appl. (1997), 178 pp. CODEN: PIXXD2 19970828 CAN 127:248357 AN 1997:579728.
    • 1997 - US 5695738. Inventors: M.B. Anderson and J. H. Musser. Steroidal C-Glycosides. Glycomed Incorporated U.S. (1997), 20 pp. US 5695738 A 19971209 CAN 128:75635 AN 1997:803505. Abstract: Compositions of sterodial glycosides are described wherein the glycoside is linked directly, or indirectly to a desired steroidal compound via a carbon, or similar stable linkage, and methods of using the compositions to treat patients by binding to and/or blocking cellular receptors for a variety of diseases including cancer, inflammation, and autoimmune diseases.
    • 1997 – US 5,688,922. Inventors: B.N. Narasinga Rao, M. B. Anderson, and J. H. Musser. Substituted Fucopyranosides. 2-Chloromethyl-3-(tri-O-benzyl-α-L-C-fucopyranoside)-1-propene and methods of making the same are described. Methods of combining this substituted fucopyranose with triterpenoid acid also are described.
    • 1997 - US 5679644. Inventors: B.N. Narasinga Rao, M. B. Anderson, and J. H. Musser. Methods of Treating Diseases Using Triterpenoid Acid Derivatives.
    • 1997 - US 5643884 (issued July 1, 1997). Inventors: Anderson, Mark Brian; Musser, John Henry. Lupane Triterpenoid Derivatives. PCT Int. Appl. (1995), 42 pp. CODEN: PIXXD2 WO 9504526 A1 19950216 CAN 122:256432 AN 1995:516374.
    • 1997 - AU7520594. Inventors: Anderson, Mark Brian; Musser, John Henry. Lupane Triterpenoid Derivatives. PCT Int. Appl. (1995), 42 pp. CODEN: PIXXD2 WO 9504526 A1 19950216 CAN 122:256432 AN 1995:516374.
    • 1997 - CA2169291. Inventors: Anderson, Mark Brian; Musser, John Henry. Lupane Triterpenoid Derivatives. PCT Int. Appl. (1995), 42 pp. CODEN: PIXXD2 WO 9504526 A1 19950216 CAN 122:256432 AN 1995:516374.
    • 1997 - EP0714291, WO9504526. Inventors: Anderson, Mark Brian; Musser, John Henry. Lupane Triterpenoid Derivatives. PCT Int. Appl. (1995), 42 pp. CODEN: PIXXD2 WO 9504526 A1 19950216 CAN 122:256432 AN 1995:516374.
    • 1997 - US 5624909. Inventors: B.N. Narasinga Rao, M. B. Anderson, J. J. Nalway, and J. H. Musser. Derivatives of Triterpene Acids as Inhibitors of Cell Adhesion Molecules ELAM-1 (E-Selectin) and LECAM -1 (L-Selectin). Abstract: Derivatives of triterpenoid acids as inhibitors of cell-adhesion molecules ELAM-1 (E-selectin) and LECAM-1 (L-selectin).
    • 1996 - WO 9636627. Inventors: Anderson, Mark Brian; Musser, John H. Process For The Preparation of Activated Glycomimetic C-Glycosides as Selectin Inhibitors. PCT Int. Appl. (1996), 132 pp. CODEN: PIXXD2 WO 9636627 A1 19961121 CAN 126:89699 AN 1997:51546.
    • 1996 - US 5527890. Inventors: M.B. Anderson, B. N. Narasinga Rao, and J. H. Musser. Derivatives of Triterpene Acids and Uses Thereof.
    • 1996 - CA 2160370. Inventors: M.B. Anderson, B. N. Narasinga Rao, and J. H. Musser. Derivatives of Triterpene Acids and Uses Thereof.
    • 1996 - EP 0693079. Inventors: M.B. Anderson, B. N. Narasinga Rao, and J. H. Musser. Derivatives of Triterpene Acids and Uses Thereof.
    • 1996 - AU 6529194. Inventors: M.B. Anderson, B. N. Narasinga Rao, and J. H. Musser. Derivatives of Triterpene Acids and Uses Thereof.
    • 1996 - WO 9424145. Inventors: M.B. Anderson, B. N. Narasinga Rao, and J. H. Musser. Derivatives of Triterpene Acids and Uses Thereof.
    • 1996 - US 5519008. Inventors: B.N. Narasinga Rao, M. B. Anderson, J. J. Nalway, and J. H. Musser. Derivatives of Triterpene Acids as Inhibitors of Cell Adhesion Molecules ELAM-1 (E-Selectin) and LECAM-1 (L-Selectin). Abstract: Triterpenoid acid derivatives have been found to have structures similar to natural ligands to the extent that these derivatives bind to natural selectin receptors including endothelial leukocyte adhesion molecule-1 (ELAM-1) and leukocyte/endothelial cell adhesion molecule-1 (LECAM-1). The molecules can be administered to the patients by themselves or in pharmaceutical formulations; in order to alleviate inflammation and/or treat other abnormalities associated with the excessive binding of leukocytes to endothelial receptors.
    • 1996 - AU 5160093. Inventors: B.N. Narasinga Rao, M. B. Anderson, J. J. Nalway, and J. H. Musser. Derivatives of Triterpene Acids as Inhibitors of Cell Adhesion Molecules ELAM-1 (E-Selectin) and LECAM-1 (L-Selectin). Abstract: Triterpenoid acid derivatives have been found to have structures similar to natural ligands to the extent that these derivatives bind to natural selectin receptors including endothelial leukocyte adhesion molecule-1 (ELAM-1) and leukocyte/endothelial cell adhesion molecule-1 (LECAM-1). The molecules can be administered to the patients by themselves or in pharmaceutical formulations; in order to alleviate inflammation and/or treat other abnormalities associated with the excessive binding of leukocytes to endothelial receptors.
    • 1996 - AU 675085. Inventors: B.N. Narasinga Rao, M. B. Anderson, J. J. Nalway, and J. H. Musser. Derivatives of Triterpene Acids as Inhibitors of Cell Adhesion Molecules ELAM-1 (E-Selectin) and LECAM-1 (L-Selectin). Abstract: Triterpenoid acid derivatives have been found to have structures similar to natural ligands to the extent that these derivatives bind to natural selectin receptors including endothelial leukocyte adhesion molecule-1 (ELAM-1) and leukocyte/endothelial cell adhesion molecule-1 (LECAM-1). The molecules can be administered to the patients by themselves or in pharmaceutical formulations; in order to alleviate inflammation and/or treat other abnormalities associated with the excessive binding of leukocytes to endothelial receptors.
    • 1996 - EP 0691813. Inventors: B.N. Narasinga Rao, M. B. Anderson, J. J. Nalway, and J. H. Musser. Derivatives of Triterpene Acids as Inhibitors of Cell Adhesion Molecules ELAM-1 (E-Selectin) and LECAM-1 (L-Selectin). Abstract: Triterpenoid acid derivatives have been found to have structures similar to natural ligands to the extent that these derivatives bind to natural selectin receptors including endothelial leukocyte adhesion molecule-1 (ELAM-1) and leukocyte/endothelial cell adhesion molecule-1 (LECAM-1). The molecules can be administered to the patients by themselves or in pharmaceutical formulations; in order to alleviate inflammation and/or treat other abnormalities associated with the excessive binding of leukocytes to endothelial receptors.
    • 1996 - WO 9405152. Inventors: B.N. Narasinga Rao, M. B. Anderson, J. J. Nalway, and J. H. Musser. Derivatives of Triterpene Acids as Inhibitors of Cell Adhesion Molecules ELAM-1 (E-Selectin) and LECAM-1 (L-Selectin). Abstract: Triterpenoid acid derivatives have been found to have structures similar to natural ligands to the extent that these derivatives bind to natural selectin receptors including endothelial leukocyte adhesion molecule-1 (ELAM-1) and leukocyte/endothelial cell adhesion molecule-1 (LECAM-1). The molecules can be administered to the patients by themselves or in pharmaceutical formulations; in order to alleviate inflammation and/or treat other abnormalities associated with the excessive binding of leukocytes to endothelial receptors.
    • 1996 - CA 2221589. Inventors: Anderson, Mark Brian and Musser, John H. Collection of Activated Glycoside Compounds and Their Biological Use.
    • 1996 - AU 5855296. Inventors: Anderson, Mark Brian and Musser, John H. Collection of Activated Glycoside Compounds and Their Biological Use.
    • 1996 - EP 0828729. Inventors: Anderson, Mark Brian and Musser, John H. Collection of Activated Glycoside Compounds and Their Biological Use.
    • 1996 - WO 9636627. Inventors: Anderson, Mark Brian and Musser, John H. Collection of Activated Glycoside Compounds and Their Biological Use.
    • 1995 - WO 9504526. Inventors: Anderson, Mark Brian; Musser, John Henry. Lupane Triterpenoid Derivatives. PCT Int. Appl. (1995), 42 pp. CODEN: PIXXD2 WO 9504526 A1 19950216 CAN 122:256432 AN 1995:516374.
    • 1994 - WO 9424145. Inventors: Rao, Narasinga; Anderson, Mark Brian; Musser, John Henry. Preparation of Glycyrrhetinic Acid Derivatives as Selectin Ligands and Leukotriene Biosynthesis Inhibitors. PCT Int. Appl. (1994), 49 pp. CODEN: PIXXD2 WO 9424145 A1 19941027 CAN 122:240077 AN 1995:468527.
    • 1994 - WO 9405152. Inventors: Rao, Narasinga; Anderson, Mark Brian; Naleway, John J.; Musser, John Henry. Derivatives of Triterpenoid Acids as Inhibitors of Cell-Adhesion Molecules ELAM-1 (E-Selectin) and LECAM-1 (L-Selectin). PCT Int. Appl. (1994), 77 pp. WO 9405152 A1 19940317 CAN 120:315817 AN 1994:315817.

     

    ................

    ................

    References

    .....

    2009BigSkyWeb.jpg

    From Principle To Practice; The Business of Science